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Abstract (English) 
 
Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term effects include 
onset of insulin resistance and cardiovascular diseases.  Increased oxidative stress and dysregulation 
of the ubiquitin-proteasome system (UPS) are implicated in protease-inhibitor (PI)-mediated cardio-
metabolic pathophysiology.  We hypothesized that PI treatment (Lopinavir/Ritonavir) elevates 
myocardial oxidative stress and concomitantly inhibits the UPS, thereby attenuating cardiac function.  
Lopinavir/Ritonavir was dissolved in 1% ethanol (vehicle) and injected into mini-osmotic pumps that 
were surgically implanted into Wistar rats for eight weeks vs. vehicle and sham controls.   
Subsequently, we evaluated metabolic parameters and heart function (ex vivo and in vivo methods) at 
baseline and following ischemia-reperfusion. PI-treated rats exhibited weight gain, increased serum 
LDL-cholesterol, higher tissue triglycerides (heart, liver), but no evidence of insulin resistance.  It also 
upregulated hepatic gene expression of acetyl-CoA carboxylase β and 3-hydroxy-3-methylglutaryl-
CoA-reductase, key regulators of fatty acid oxidation and cholesterol synthesis, respectively. Further, 
PI-treated hearts displayed impaired UPS, increased superoxide dismutase (SOD) activity and 
unaltered superoxide levels, and elevated peroxisome proliferator-activated receptor-γ coactivator 1-
α (PGC-1α) peptide levels.  Perfusion data revealed contractile dysfunction at baseline and following 
ischemia-reperfusion, while post-ischemic hearts exhibited decreased ATPase specific activity vs. 
matched controls. Early changes initiated by PI treatment resemble the metabolic syndrome and 
reflect a pre-atherogenic profile.  Moreover, the effects of PIs on cardiac contractile function may in 
part be triggered by impaired UPS activity together with strain on the mitochondrial energetic system.  
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Our study alerts to cardio-metabolic side effects of PI treatment and raises the question of the most 
appropriate co-therapies for patients on chronic antiretroviral treatment. 
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Abstract (Afrikaans) 
 
Alhoewel anti-retrovirale behandeling MIV-VIGS morbiditeit/mortaliteit verlaag, bestaan daar 
langtermyn effekte soos die aanvang van insulienweerstandigheid en kardiovaskulêre siektes.  
Verhoogde oksidatiewe stres en wanregulering van die ubikwitien-proteosoomsisteem (UPS) word 
geïmpliseer met protease-inhibeerder (PI) gemediëerde kardio-metaboliese patofisiologie.  Ons 
hipotetiseer dat PI behandeling (Lopinavir/Ritonavir) miokardiale oksidatiewe stres verhoog, en 
gevolglik die UPS inhibeer waardeur dit kardiale funksie verander.  Lopinavir/Ritonavir is in 1% etanol 
(draer) opgelos en in ‘n mini-osmotiese pomp ingespuit wat chirurgies in Wistar rottes ingeplant is vir 
agt weke vs. draer en valskontroles.  Gevolglik het ons die metabolise parameters en hartfunksie (ex 
vivo en in vivo metodes) op basislyn en na afloop van ischemie-reperfusie ondersoek.  PI-behandelde 
rotte het ‘n toename in massa getoon asook verhoogde serum LDL-cholesterol, hoër 
weefseltrigliseriede (hart, lewer), maar geen bewys van insulienweerstandigheid nie.  Dit het ook 
hepatiese asetielko-ensiem A karboksilase β en 3-hidrokise-3-metielglutariel KoA reduktase 
geenuidrukking opwaarts gereguleer, wat sleutel reguleerders van vetsuuroksidasie en 
cholesterolsintese onderskeidelik is.  Verder, het PI-behandelde harte ingeperkte UPS, verhoogde SOD 
aktiwiteit en onveranderde superoksiedvlakke vertoon, asook verhoogde peroksisoomproliferator-
geaktiveerde reseptor-γ ko-aktiveerder 1-α (PGC-1α) peptiedvlakke.  Perfusie data toon kontraktiele 
wanfunskionering gedurende basislyn en na afloop van ischemie-reperfussie, terwyl post-ischemiese 
harte verlaagde ATPase spesifieke aktiwiteit vs gepaarde kontrole vertoon.  Vroeë veranderinge wat 
deur PI behandeling veroorsaak word, kom ooreen met die metabolise sindroom en reflekteer op ‘n 
pre-aterogeniese profiel.  Bowendien kan die effekte van PIs op kardiale kontraktiele funksie deels 
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veroorsaak word deur die ingeperkte UPS aktiwiteit tesame met die las op die mitochondriale energie 
sisteem.  Ons studie waarsku teen kardio-metaboliese newe effekte met PI behandeling en rig die 
vraag; wat die mees gepaste ko-behandeling vir pasiënte op chroniese anti-retrovirale behandeling is. 
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Introduction 
 
Human immunodeficiency virus (HIV) infection has increased dramatically in the last two decades, 
with more than 5 million of the 40 million globally infected individuals residing in sub-Saharan Africa 
1,2. The development of acquired immunodeficiency syndromes (AIDS) due to chronic inflammation 
decreases the quality of life amongst sufferers and places their long-term health in jeopardy. In 
parallel, the ever-increasing obesity epidemic developing alongside HIV infection with increased 
cardiovascular complications presents a dual burden of disease. With the advent of highly active 
antiretroviral therapy (HAART) life expectancy and quality has drastically improved for those infected 
3,4, however, there are increased concerns regarding HAART-mediated metabolic derangements and 
its potential risk for cardiovascular diseases (CVD) in the long-term. Further, certain classes of 
antiretroviral (ARV) drugs e.g. protease inhibitors (PIs) are implicated in these perturbations, although 
mechanistic insight is lacking. This review will highlight the contributions of the HIV infection itself, 
HAART, and the specific HAART drug class the PIs to the onset of cardio-metabolic complications.  
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HIV infection and cardiovascular diseases 
HIV infection is characterized by a compromised immune system and subsequent chronic, life-long 
inflammation and the development of AIDS. Cardiac abnormalities were noted as early as 1989 5,6 
(pre-HAART era) and included dilated cardiomyopathy, endo-, myo- and peri-carditis, and pulmonary 
hypertension 5–8. Prevalence during this time period was between 28 and 73% 5,7,9. HIV is able to 
directly infect cardiac tissue 10, though this may be attributed to the stage of HIV/AIDS, but 
nonetheless compounds future health outcomes and survival of an HIV-infected individuals. During 
the HAART era, it is important to understand the relative contributions of both antiretrovirals and HIV 
infection in the onset of CVD and related manifestations, especially since HIV infection is a potential 
risk factor for CVD (to be discussed later).  
 Co- and multi-morbidity patterns in HIV infection are alarming. For example, when 
comorbidities are stratified by HIV status, age and severity; not only was HIV infection a risk for future 
health concerns, but long-term HAART is also linked to detrimental cardiovascular consequences 11. 
Further, disease advancement with HIV infection is associated with renal, vascular and pulmonary 
complications that are commonly found in ageing populations (Fig. 1). When morbidity patterns are 
stratified by obesity by employing the body mass index (BMI) 12, up to 65% of HIV-infected individuals 
have multi-morbidities with obesity exacerbating these effects. A long-term study investigated the 
expected survival and mortality rates of an HIV-infected population during 1995 to 2005 13, where 
each case of HIV infection was matched with up to 99 individuals according to age, gender and 
seronegative status. From the age of 25 years, the HIV-infected cohort of 3, 990 individuals displayed 
lower survival rates than their healthy counterparts (19.9 years vs. 51.1 years). However, during the 
period 2000 – 2005, survival increased to 32.5 years and coincided with the availability of HAART.  
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Figure 1. HIV infection and HAART: detrimental side effects. Multiple organ systems are adversely 
affected by infection with the HI virus, and treatment with HAART drugs (e.g. protease inhibitors) 
further exacerbate side-effects with their own unique pathologies. Ultimately the patient’s quality of 
life (encompassing many facets) becomes compromised, leading to an increased risk for future 
cardiovascular and organ pathologies. AIDS – acquired immunodeficiency syndrome, IR – insulin 
resistance, T2DM – type 2 diabetes mellitus, CVD – cardiovascular diseases. 
 
Chronic immune activation presents quite a challenge to the myocardium and key studies 
highlight the role of HIV in the cardiovascular disease burden. Firstly, Becker and colleagues (2010) 14 
observed that HIV-infected HAART naïve patients with acute coronary syndrome (ACS) exhibited less 
traditional CVD risk factors than their HIV negative counterparts (with ACS), but a significantly higher 
thrombotic burden (43% vs. 17%) and different angiographic characteristics. Not only were these 
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results confirmed in similar studies 15,16, but data pointed towards a distinct pathogenesis of 
cardiovascular abnormalities in HIV-infected versus healthy individuals. Here HIV-positive individuals 
with ACS were compared to HIV negative and diabetic non-ACS counterparts, and although the extent 
of multi-vessel disease in all three groups was similar, HIV-positive individuals were much younger 
and had less complex lesions than their controls. Further, the degree of subclinical coronary 
atherosclerosis was elevated within the HIV-infected population 16. These studies and others are 
presented in Table I. Therefore, the nature of HIV itself allows for viral-mediated activation of 
pathways that contribute to the development of thrombotic and atherosclerotic disease infection in 
addition to the traditional risk factor pathways.  However, the focus has now shifted from 
opportunistic infections to metabolic and cardiovascular complications, especially within the context 
of HAART and extended lifespans. The focus of this review article is therefore on HAART-linked onset 
of cardio-metabolic complications, with particular emphasis on the damaging role of PIs.  
 
Table I. HIV ± HAART and the risk for MI and cardiovascular complications (clinical studies). 
Author Outcome 
Jericó C 17, de Saint Martin L 18, Lo J 16 Atherosclerosis, coronary-intima-media-
thickness alterations, subclinical 
atherosclerosis 
Lijfering WM 19, Sullivan PS 20, Maggi P 21 Thrombosis, vascular lesions 
Majluf-Cruz A 22, Gazzaruso C 23, Lekakis J 24, 
Boccara F 25, Butt AA 26 
ACS, heart failure, CAD, MI 
Abbreviations: ACS – acute coronary syndrome, CAD – coronary artery disease, HAART – highly active 
antiretroviral therapy, HIV – human immunodeficiency virus, MI – myocardial infarction. 
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PIs and cardiovascular consequences 
ARVs increase life expectancy and quality of life of HIV-positive individuals and its usage is essential to 
combat HIV’s detrimental effects. ARVs inhibit the viral lifecycle at key stages and the combination of 
different classes as HAART constitutes critical weaponry in the fight against HIV/AIDS (Fig. 2). For 
example, an extensive study comprising of 41, 213 HIV-infected patients exposed to HAART for ≥72 
months revealed that ARVs significantly improved death rate versus HAART-naïve patients (20.9 
deaths per 100 person-years observation vs. 5.2 deaths) 27.  
PIs act by inhibiting HIV aspartyl protease leading to the production of immature and non-
infectious viral particles 28.  More than 10 HIV PI-type drugs have been developed since the advent of 
HAART in 1995 29, with Lopinavir/Ritonavir the latest, and the drug of choice for this study.  Lopinavir 
and Ritonavir are heterocyclic compounds with the liver a major site for Lopinavir metabolism.  Kumar 
et al. (2004) 30 investigated metabolism of Lopinavir in a number of species and established that after 
uptake and release into circulation, most of it binds to plasma proteins (>97%).  Moreover, they found 
that Lopinavir was taken up, to varying degrees, by most tissues including the heart (in rats).  
However, it poorly penetrated the blood-brain barrier. Lopinavir is metabolized to a number of 
oxidative metabolites, although the parent compound is the major circulating drug with only a small 
percentage of metabolites present 30,31. Such metabolites are also less potent inhibitors of HIV 
protease 32. Since Lopinavir is metabolized by the hepatic enzymes CYP3A4 and CYP3A5 31, its 
circulating concentrations are inadequate to suppress viral replication (if employed as monotherapy). 
However, Ritonavir potently inhibits CYP3A4 and CYP3A5, thereby ensuring higher Lopinavir plasma 
concentrations 33,34. In light of this, Ritonavir was co-formulated with Lopinavir, i.e. Kaletra ™ and 
Aluvia ™ (the latter with improved heat stability) 33.  
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Figure 2. HIV lifecycle and antiretroviral drug targets. 1. The virus docks and infiltrates the cell 
membrane of the host cell. 2. Single-strand viral RNA enters the host nucleus where 3. Viral reverse 
transcriptase transcribes single-stranded RNA. 4. Production of double-stranded RNA. 5. RNA enters 
the nucleus and integrates itself within the host’s DNA with integrase. 6. The host’s transcription 
system allows viral mRNA production for viral proteins, 7. Gag and Gag-pol multi-protein complexes 
assemble and bud at the host’s cell wall where proteases cleave proteins and mature viral particles. 
HAART can inhibit key viral enzymes at various stages of the viral life cycle – reverse transcriptase 
(RTI), nucleosides and non-nucleoside reverse transcriptase inhibitors (NRTI, NNRTI), integrase 
inhibitors and protease inhibitors (PI). DNA – deoxyribonucleic acid, HIV – human immunodeficiency 
virus, mRNA – messenger RNA, RNA – ribonucleic acid. 
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PIs are also implicated in the onset of cardiovascular complications with increased risk for 
myocardial infarction (MI) and coronary syndromes. In one of the largest clinical studies assessing the 
risk for MI with HAART, the Data Collection for Adverse events of Anti-HIV Drugs (DAD) Study Group 
recruited 23, 468 HIV-positive patients on HAART 35–37. Here cumulative exposure to HAART was 
linked to a strong increase in the incidence of MI (26% relative change), with PIs contributing the most 
significant risk. Although the absolute risk for MI was low when adjusted for confounding parameters, 
HAART and PIs exacerbated traditional CVD risk factors such as cholesterol and lipid abnormalities, 
and type 2 diabetes mellitus (T2DM). Similar results were found in large cohort studies where the 
absolute rate of MI events remains low  38,39 and PIs are significantly associated with the occurrence 
of MI 20,35,36,38–40. Further, cumulative time exposed to HAART regimens (including PI) can increase 
mortality 27,37,41and hospitalization for cardiovascular complications 42 in the long-term.  
Echocardiographic abnormalities are also associated with the use of Ritonavir. For example, 
baseline echocardiography revealed significant rates of left ventricular systolic and diastolic 
dysfunction, pulmonary hypertension and left atrial enlargement in an HIV-infected cohort 43. Though 
some studies do not support a link between PIs and atherosclerosis 20,44 (due to minimal differences 
between PIs and other antiretrovirals (ARV) in HAART), many others do report a clear link with the 
development of subclinical atherosclerotic lesions 17,18,21,45  and thrombotic environments 19,22. Studies 
linking cardiovascular and MI incidence are summarized in Table II.  
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Table II. PI treatment and the risk for MI and cardiovascular complications (clinical studies). 
Author Outcomes 
Friis-Møller N 35,36, Smith C 37, 
Holmberg SD 38, Mary-Krause M 39, 
Durand M 40, Lang S 46, Coplan PM 47 
PIs ↑ AMI events, associated with MI risk, and 
↑ risk for CVD 
Triant VA 41, Klein D 42, Lifson AR 48 PIs ↑ mortality and/or hospitalization due to 
cardiovascular complications 
Mondy KE 43 ECG abnormalities with PI use 
Sullivan PS 20, Lyonne L 44 Minimal link with PIs and atherosclerotic 
lesions 
Maggi P 21, Bernal E 45, de Saint Martin 
L 18, Jerico C 17 
PIs associated with subclinical atherosclerotic 
lesions 
Abbreviations: AMI – acute myocardial infarction, CVD – cardiovascular disease, ECG – electro-
cardiogram, MI – myocardial infarction, PI – protease inhibitor. 
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PIs and changes to lipid metabolism 
HIV PIs likely exert direct and indirect effects (e.g. altered metabolism – systemic and organ-related) 
on the cardiovascular system.  Its’ direct effects on the heart is less well understood compared to 
indirect changes elicited.  In terms of the latter, PIs can trigger metabolic side-effects that resemble 
the metabolic syndrome (MetS), a combination of risk factors that predispose to future onset of 
T2DM and CVD 49.  Various definitions and cut-off parameters exist for the MetS but the main risk 
factors include abdominal obesity, atherogenic dyslipidemia, insulin resistance (IR) (with or without 
glucose intolerance), elevated blood pressure, pro-inflammatory status and a pro-thrombotic state 49–
51.  In support, human- 52–58, animal- 59–61 and cell-based 62–65 studies demonstrate that increased 
plasma cholesterol and triglyceride (TG) levels, and the development of lipodystrophy and IR are the 
most common metabolic perturbations found with PI treatment. Together such metabolic 
derangements trigger inflammation, stress the myocardium 66,67, and may potentially predict the 
onset of IR and cardiac dysfunction 56,68 . Table III summarizes the main clinical findings relating to 
alterations in lipid metabolism with PIs.  
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Table III. Lipid changes associated with PI therapy (clinical studies). 
Author Outcomes 
Behrens G 52, Bastard J 53, Carr A 54, 
Dong K 55, Gan S 56, Tsiodras S 57, 
Floris-Moore M 58 
↑ plasma cholesterol, ↑ TG, LD and IR 
development with PIs 
Sekhar R 69 LD, ↑ REE, ↑ FAO, ↑ FFA 
Mulligan K 70, Bernal E 45, Carr A 
66,71,72, Gazzaruso C 23, Biron A 73 
Anthropometric changes accompanied with 
development of dyslipidemia and MetS with 
PI treatment ≥ 12 months 
Symbols: ↑ - increase. Abbreviations: FAO – fatty acid oxidation, FFA – free fatty acid, IR – insulin 
resistance, LD – lipodystrophy, MetS – metabolic syndrome, PI – protease inhibitor, REE – resting 
energy expenditure, TG - triglycerides. 
 
With lipodystrophy an imbalance in fat partitioning occurs with lipoatrophy occurring at the 
extremities (e.g. lower legs, arms, face) and central accumulation of fatty tissue especially at 
subcutaneous sites (e.g. waist, hips, neck). The over-accumulation of subcutaneous fat elevates 
cholesterol and TG levels within the abdominal area and cause dyslipidemia. Further, the increased 
burden of lipodystrophy with HIV infection can alter fatty acid (FA) metabolism. For example, Sekhar 
and colleagues (2002) 69 found that HIV-positive men with lipodystrophy displayed higher resting 
energy expenditure rates, elevated free fatty acids (FFA) and fatty acid oxidation (FAO) versus healthy 
non-infected controls. Moreover, lipid parameters measured in these individuals were highly 
indicative of MetS.  
Stellenbosch University  http://scholar.sun.ac.za
35 
 
Studies assessing anthropometric changes established that PI-mediated metabolic 
derangements may occur before the onset of overt body changes such as increased waist 
circumference and weight gain 70. However, dyslipidemia and MetS can manifest simultaneously with 
anthropometric alterations, especially for PI therapy longer than 12 months 23,45,71–73. Lastly, 
alterations to glucose metabolism are linked to PIs, e.g. it can impair glucose tolerance as well as 
whole-body glucose disposal,  glucose uptake, transport and phosphorylation and cause IR at 
peripheral sites such as skeletal muscle 52,74,75. These data indicate that HIV PIs have far-reaching 
consequences on metabolism that may impact on cardiovascular function.  How does this occur?  It is 
likely that PIs act early-on at the molecular level to activate key metabolic pathways, and initiate a 
cascade of detrimental alterations that progressively contribute to the development and presentation 
of dyslipidemia, lipodystrophy and weight gain.  This then provides impetus for further downstream 
lipid- and glucose-mediated derangements and related pathophysiology such as oxidative stress, 
mitochondrial impairment, IR/T2DM and the onset of CVD. 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
36 
 
Molecular mechanisms underlying PI perturbations 
The molecular mechanisms underlying cholesterol and FA synthesis strongly implicate transcriptional 
(sterol-regulatory element binding protein [SREBP] and peroxisome proliferator-activator gamma 
coactivator one alpha [PGC-1α]) and the proteasomal degradation pathway in this process.  
 
SREBPs 
 The SREBPs are master transcriptional regulators of enzymes required for the production of 
cholesterol, TG and FA synthesis 76. SREBPs are basic helix-loop-helix-leucine-zipper (bHLH-LZ) 
transcription factors 77 and is bound to the endoplasmic reticulum (ER) and the nuclear membrane. 
This precursor SREBP consists of 3 connected parts spanning the sarcolemma: i.e. an NH2-terminal 
domain, two hydrophobic trans-membrane-spanning domains, and a COOH-terminal domain. The 
SREBP gene is located on two  chromosomes, namely 17p11.2 (generates SREBP-1a and -1c) 78 and 
22q13 (generates SREBP-2) 79.   
Tontonoz et al. (1993) earlier referred to the SREBP-1c isoform as adipocyte differentiation 
dependent factor 1 (ADD1) since it plays a role in adipogenesis 80.  SREBPs are ubiquitously expressed, 
i.e. SREBP-1a in cells with high proliferative capacity 81 while SREBP-1c is the dominant form in liver, 
white adipose, skeletal, cardiac, adrenal, and brain tissues.   
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The SREBP pathway is an example of end-product feedback regulation of gene transcription 
(Fig. 3). The depletion of sterol levels triggers the pathway where SREBP cleavage activating protein 
(SCAP) associates with the SREBP precursor protein on the ER. Site 1 and Site 2 proteases (S1P, S2P) 
proteolytically cleave the hydrophobic trans-membrane domain from the NH2-terminal and SREBP is 
translocated into the nucleus 82,83. Thereafter SREBP binds to sterol-response elements (SRE) (5’-
TCACNCCAC-3’) or E-boxes (5’-CANNTG-3’) 84 within the promoter regions of the SREBP and target 
genes thereby initiating gene transcription. Isoforms of the SREBP-1, -2 and target gene proteins 
further activate FA and cholesterol biosynthesis genes 76,85–87 resulting in increased production of 
sterols. Negative feedback regulates the pathway once appropriate sterol levels are produced.  
Intra-nuclear SREBP levels are also regulated by proteasomal degradation. Here the 26S and 
20S proteasomes first ubiquitinate and then degrade active nSREBPs 88–90. However, if proteasome 
inhibitors are administered, nSREBP levels stabilize leading to increased gene expression of target 
genes 88. Furthermore, SREBP-1a and 2 contain small ubiquitin-related modifiers that are able to 
decrease their transcriptional activity by sumoylation 91.  As sterol levels are replenished, the SREBP 
transcriptional pathway described is blunted, while enzyme activity and sterol production declines in 
parallel. 
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Figure 3. The SREBP pathway. 1) Depletion of sterol levels triggers pathway activation. 2) SREBP 
cleavage activating protein is stimulated (SCAP). 3) SCAP associates with the COOH-terminal of the 
SREBP precursor protein. 4) Site 1 and Site 2 proteases (S1P, S2P) proteolytically cleave the 
hydrophobic trans-membrane domain and release it into the cytosol. 5) Active SREBP is translocated 
into the nucleus via importin. 6) SREBP binds to sterol-response elements (SRE) or E-boxes within the 
promoter regions of the SREBP and target genes. 7) Isoforms of the SREBP gene (SREBP-1 and 2) are 
transcribed. 8) SREBP-1, -2 and target gene proteins further activate fatty acid (FA) and cholesterol 
biosynthesis genes 76,85–87 increasing sterol production. Negative feedback along with proteasomal 
recycling of SREBP-1 and -2 regulate the pathway. 
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The three SREBP isoforms allow for specific activation of target genes. Here SREBP-1 targets 
lipogenic genes for FA and TG biosynthesis 92 while SREBP-2 activates transcription of cholesterogenic 
genes 93. Different organs also possess various lipogenic capacities, with liver and adipose tissue 
having a higher capacity 94 compared to muscle and heart tissue. This is to be expected since the 
latter are major sites for FAO 95. The distinguishing mechanisms occur at the gene promoter level, i.e. 
lipogenic genes containing  SRE/SRE-like elements are largely activated by SREBP-1a, while 
cholesterogenic genes are more likely be activated by SREBP-1c and 2 containing variations of the 
SRE/SRE-like elements within their promoters 96.  
Acetyl-CoA is an important player in terms of actual SREBP gene targets. It is the precursor for 
the formation of lipid entities and diverges according to its end-product. Acetyl-CoA is converted to 3-
hydroxy-3-methyl-glutaryl-coA (HMG-CoA) by HMG-CoA-synthase, and thereafter reduced to 
mevalonate via HMG-CoA-reductase. Mevalonate is thereafter further metabolized and ultimately 
produces cholesterol. The conversion of acetyl-CoA to malonyl-CoA is the first step of FA synthesis in 
lipogenic tissues such as the liver and fat cells. Fatty acid synthase (FAS) catalyzes the production of 
saturated FAs that are shunted to monosaturated FAs and fatty-acyl-CoA via stearoyl-CoA-destaurase 
2 (SCD2). Ultimately, glycerol-3-posphate-acyltransferase-[mitochondrial] (GPAM) converts fatty-acyls 
to phospholipids (TGs) and FAs (extensively reviewed in 76,87). Genes encoding for acetyl-CoA-
carboxylase (ACC) 97,98, FAS 98,99, GPAM 100, HMG-CoA-reductase 101–104, HMG-CoA-synthase 105, SCD2 
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106 and  low-density lipoprotein receptor (LDL-R) 98,107 all contain SREBP binding sites and are thus 
directly regulated by SREBP and sterol levels within the cell.  
A number of in vitro 108,109 and in vivo 109–112 studies show that PIs can exert lipid-related 
perturbations at the transcriptional level. For example, PIs inhibit adipocyte differentiation and 
transcription of FA-related genes in 3T3-L1 adipocytes when treated with therapeutic concentrations 
for ten days 108. Furthermore, microarray analyses of 3T3-L1 adipocytes treated with PIs indicate 
robust transcriptional effects as genes involved in inflammatory cytokine production, oxidative stress, 
stress response, apoptosis and lipid metabolism were markedly altered with treatment 61,113,114. 
Similar effects were found in cultured hepatocytes 109 and also when employing animal models 109–112, 
e.g. PIs elevated lipid production in mice (increased plasma TGs and cholesterol) while enhancing FAS 
protein levels in parallel 109. Further, genes involved in FA synthesis and oxidation were up- and down-
regulated, respectively, following seven days of PI administration to male Sprague-Dawley rats 110. 
Interestingly, a Western-type diet administered together with Ritonavir (fourteen days) resulted in 
the exacerbation of the hyperlipidemic phenotype, hepatic steatosis and hepatomegaly 111. However, 
animals co-administered a normal diet still showed marked levels of plasma lipids and activation of FA 
and cholesterol synthesis compared to PI-naïve controls. Here SREBP accumulated within the nucleus 
of hepatic and adipose tissues even though mRNA levels remained unaltered with PI therapy.  
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Apolipoprotein B (ApoB) levels are essential for the production of very-low density lipoprotein 
(VLDL) particles and contribute to the cholesterol pool. ApoB is hydrolyzed from TG-containing 
chylomicrons via lipoprotein lipase (LPL) and released from the liver into circulation as VLDL. 
Inhibition of the proteasomal degradation of ApoB leads to its accumulation; however, this does not 
translate directly in to elevated VLDL production as secretion of ApoB is also necessary in addition to 
its synthesis 115,116. If de novo lipid and cholesterol synthesis are activated (e.g. via PI-mediated 
accumulation of SREBPs), this can contribute to an increase in the production of lipoproteins and 
ApoB 117. Liang and colleagues (2001) 60 demonstrated that PIs can also inhibit LPL (in addition to 
proteasomal degradation of ApoB), with the subsequent accumulation of ApoB and activation of lipid 
synthesis. ApoB and lipoproteins are also significant factors in the development of atherosclerosis 
with HIV infection and antiretroviral therapy (ART) 118. 
SREBPs are recycled via the ubiquitin-proteasome system (UPS) and this ensures lipid and 
cholesterol metabolism are optimally maintained. However, when the UPS is inhibited, levels of 
ubiquitinated SREBPs increase and subsequent activation of lipid genes 88. Notably, ubiquitination of 
SREBP-1 occurs while it is bound to the promoter region of its target gene. Here the E3 ligase Fbw7 
associates with the bound SREBP-1 to attach a ubiquitin moiety and the UPS can then remove and 
degrade SREBP, halting transcription of the target gene 119. Thus SREBP levels are controlled by DNA 
binding, and UPS inhibition effectively means SREBPs remain bound to DNA promoters for longer. This 
in turn can increase target gene transcript levels without directly affecting SREBP levels.  
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Together this indicates that PIs can alter lipid metabolism by the SREBP transcriptional 
pathway and via its direct effect on key lipogenic and cholesterogenic enzymes that ultimately leads 
to an increased risk for future atherosclerotic and cardiovascular complications (Fig. 4). 
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Figure 4. The effects of PIs on lipid metabolism. PIs inhibit proteasomal degradation of SREBP causing 
an accumulation of SREBP bound to the promoter region of target genes essential for the generation 
of metabolic enzymes catalyzing cholesterol and lipid synthesis pathways in liver and adipose tissues. 
Ultimately, the over-accumulation of fatty acids and cholesterol leads to hyperlipidemia and 
hypercholesterolemia – ensuring an atherogenic state within the myocardium and elevated risk for 
cardiovascular pathologies such as myocardial infarction and diabetes. ACC – acetyl coenzyme A 
carboxylase, ApoB – Apolipoprotein B, FA – fatty acids, FAS – fatty acid synthase, GPAM –glycerol-3-
phosphate-acyltransferase-[mitochondrial], HMG-CoA-R/S – 3-hydroxy-3-methyl-glutaryl-CoA-
reductase/synthase, HDL/LDL – high/low-density lipoprotein, LPL – lipoprotein lipase, MetS – 
metabolic syndrome, PI – protease inhibitor, SREBP – sterol regulatory element binding protein, SRE – 
sterol-response element, UPS – ubiquitin proteasome system. 
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HIV PIs and the ubiquitin-proteasome system 
The UPS is an important regulatory system that exists to monitor protein turnover and removal of 
cellular debris, expired and/or damaged proteins. This pathway is especially important in cardiac cells 
where a high rate of protein turnover, energy requirement and physical stress occur and protein 
quality control is vital 120–122. The UPS is a non-lysosomal degradation pathway involved in many 
cellular processes such as transcriptional regulation 123, mitochondrial protein turnover and 
function124–128, cardiac ion channels and sarcomeric protein integrity 121,129. The main steps of the UPS 
involve tagging a selected protein with a ubiquitin moiety and proteolysis via the proteasome 
complex (reviewed in 120).  
Ubiquitination occurs via 3 enzymes that require ubiquitin - E1, conjugation of ubiquitin - E2, 
and attachment via ligase - E3 (ATP dependent reactions). The 26S proteasome is a multicatalytic 
multi-unit complex consisting of a 20S proteolytic core capped at each end by 19S components (Fig. 
5). The 20S catalytic subunit degrades proteins via its chymotrypsin-, trypsin- and caspase-like 
activities (ATP-independent process). 
Mitochondrial proteins make up the bulk of ubiquitinated proteins (  38%) with those in the 
cytosol comprising approximately 27% 130. The majority of mitochondrial electron transport chain 
(ETC) complexes and key contractile proteins possess ubiquitin binding sites and therefore act as 
ubiquitin substrates. These include F1F0-ATPase subunits, flavoproteins, NADH-ubiquinones, 
sarcoplasmic/endoplasmic reticulum ATPase 2 (SERCA2), desmin, contractile machinery and cardiac 
ion transporters 130. Since the mitochondrion is a powerhouse of energy metabolism it is essential 
that it possesses in-house mechanisms for protein quality control.  
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Figure 5. The ubiquitin-proteasomal degradation system (UPS). The UPS is sequentially activated 
with 3 key enzymes. 1) E1 activates and prepares ubiquitin. 2) E1 associates with ubiquitin to form a 
complex. 3) The conjugating enzyme E2 associates with the E1-Ub complex. 4) The conjugation of the 
Ub moiety and E3 on the target protein which then binds to the multicatalytic proteasome. 5) The 
proteasomal activities of the various subunits ensure that the target protein is degraded. 6) Ub 
dissociates from the complex and peptides are released into the cytosol for further processing. Ub – 
ubiquitin. 
 
 
Mitochondria contain ubiquitin activating enzymes (E1) and E3 ligases found within the outer 
mitochondrial membrane (OMM) 131–133. However, the proteasome is not present within 
mitochondria raising the question how mitochondrial proteins are actually ubiquitinated and 
degraded by the proteasome.  Here mitochondrial-associated degradation (MAD) plays a role, i.e. 
mitochondrial E1 tags proteins for ubiquitination, with subsequent retro-translocation to the OMM. 
This is followed by further ubiquitination by the E3 ligases present on the OMM124–128. Emerging data 
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support this notion, e.g. Margineantu et al. (2007) 134 found that the F1F0-ATPase residing at the inner 
mitochondrial membrane (IMM) was retro-translocated to the OMM, ubiquitinated and subjected to 
proteolysis. The study also showed that proteasomal inhibitors caused mitochondrial protein 
accumulation, e.g. cyclo-oxygenase 1 (COXI). In support, others reported similar results for uncoupling 
protein 3 (UCP3) 135. Indeed, proteasomal inhibition may leave “a path of destruction in its wake”, e.g. 
certain conditions such as Parkinson’s disease are associated with the accumulation of ubiquitinated 
proteins and defective degradation 136. Moreover, accumulation of especially transcription factors and 
enzymes may incorrectly alter signaling pathways and thereby elicit detrimental consequences.    
The intracellular redox status also has a significant impact on UPS function. The 26S 
proteasome is particularly sensitive to its oxidative environment, and lipid peroxidation can inhibit 
cardiac 20S proteasome activity 137,138. Oxidatively modified proteins are known substrates for 
ubiquitination 139,140 and improper removal may increase the overall intracellular oxidant burden 
within the cell. Paradoxically, oxidative stress can also inhibit UPS activity and increase the generation 
of free radicals 136,140–142. This ultimately places greater oxidative stress on the cell and anti-oxidant 
systems, and may create a vicious cycle of perpetual inhibition of proteolysis and accumulation of 
ubiquitin aggregates.  
HIV PI-mediated alterations in the UPS could play havoc with metabolism and potentially 
predispose patients to lipid accumulation, and ultimately atherosclerotic phenotypes (Fig. 6). For 
example, previous work found that Ritonavir is a competitive inhibitor of some proteasome subunits 
89, while microarray analyses revealed that rats acutely treated with Ritonavir displayed a marked 
increase in gene and protein content for proteasomal components 143. Further evidence show that 
HIV-1 itself can directly interact with the proteasome and decrease the host’s immune response 
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144,145. The viral infectivity factor (Vif) of HIV targets the cytidine deaminase APOBEC3 protein for 
ubiquitination and subsequent degradation, hindering C-to-U mutations within the viral DNA to 
inhibit viral replication 145. This indicates that both the virus and PIs provide a double blow to the UPS 
and may therefore serve as a starting point for metabolic perturbations via SREBP-1 and 
mitochondrial metabolism. In light of the literature discussed, mitochondrial metabolism is implicated 
as a downstream effector since the PGC-1α, the SREBPs and the UPS pathways play a central role in 
this process.   
 
 
Figure 6. The effect of PIs on the ubiquitin-proteasome system (UPS).  
PIs competitively bind to and inhibit proteasomal subunits, thereby decreasing its ability to degrade 
and recycle target proteins. This results in an accumulation of ubiquitinated proteins within the cell. 
19S and 20S – proteasomal subunits, PI – protease inhibitor, Ub – ubiquitin. 
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HIV PIs: calcium signaling and impulse propagation 
Excitation-contraction coupling (ECC) refers to the mechanism whereby an electrical signal is 
propagated through nerve cells in the heart and transformed into a chemical message to induce 
cross-bridge formation and contraction of myofibers, known as the sliding filament theory. 
Stimulation occurs via autonomic signaling from the brain/cerebral vertebrae and travels down to the 
sinal-atrial (SA) node, more commonly known as the “pace-maker” of the heart.  
 Depolarization of the SA node occurs due to a difference in the relative charge across the 
neuron membrane and is propagated further as an action potential provided a great enough potential 
is reached. Action potentials eventually travel down the transverse T-tubules of individual cardiac 
muscle fibres and cause the opening of the voltage-dependent dihydropyridine-sensitive L-type 
calcium channel, which in turn allows the influx of relatively small amounts of calcium into the 
cytosolic compartment (known as “trigger calcium”). The binding of calcium ions to the ryanodine 
receptor (RyR) present on the sarcoplasmic reticulum (SR) results in its activation to allow an efflux of 
intra-sarcolemmal calcium into the cytosol. This is known as the calcium-induced calcium release 
(CICR) 146. Calcium is now able to bind to the troponin-tropomyosin complex bound to the actin 
filament to expose its myosin binding site and thus allow for the attachment of myosin to actin. With 
the aid of 5’-adenosine triphosphate (ATP) a cross bridge is formed and the filaments slide past each 
other and cause the myofiber to contract. To release this bond, ATP must be hydrolyzed to ADP and 
inorganic phosphate (iP) and calcium removed via 5’-adenosine triphosphate synthase (ATPase) in the 
cytosol. Calcium is then sequestered and transported back into the SR lumen via another ATPase, 
SERCA. Calcium can also be taken up by the sodium-calcium exchanger (NCX) in a ratio of 3:1 (Na+: 
Ca+2). This represents one cycle of ECC under homeostatic conditions (Fig. 7). 
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Figure 7. Excitation-contraction coupling (ECC) and calcium homeostasis. 1) Action potential (AP) 
received from a motor neuron travels down the transverse T-tubule of the muscle fiber and 
depolarizes the SR membrane. 2) The calcium channel present on the SR membrane opens and allows 
a small amount of calcium into the SR cytosol. 3) Calcium activates the ryanodine receptor (RyR). 4) A 
great efflux of calcium from the SR lumen into the cytosol occurs and is termed calcium-induced 
calcium release (CICR). 5) Calcium now binds to the troponin-tropomyosin complex exposing the 
myosin binding site on acting and allows for cross bridge formation. 6) Contraction takes place with 
the aid of ATP and calcium dissociates thereafter. 7) Phospholamban is phosphorylated to allow the 
SERCA channel to become activated. 8) Reuptake of calcium back into the SR lumen by SERCA and 
NCX channels.  
AP – action potential, Ca+2 – calcium, NCX – sodium-calcium exchanger, RyR – ryanodine receptor, PLB 
– phospholamban, SERCA – sarcoplasmic-endoplasmic reticulum calcium ATPase, SR – sarcoplasmic 
reticulum, Tm – tropomyosin, Tn – troponin.  
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However, under oxidative conditions (e.g. HIV infection, chronic inflammation), ECC can 
become disrupted resulting in detrimental consequences for cardiac myofiber physiology. The RyR, 
SERCA and NCX all possess sulfhydryl (SH) groups of cysteine residues that can be modified by 
oxidation/reduction to alter channel sensitivity. For example, the RyR SH-groups are reduced to thiols 
thereby keeping the channel open 147–150, while the SERCA-2a 151–156 and NCX SH-groups 157–159 are 
oxidized rendering it inactive and unable to pump cytosolic calcium back into the SR. The 
consequence is calcium overload that leads to damaging downstream effects at both the 
mitochondrial and contractile levels; namely, a further exacerbation of ionic imbalance and toxicity, 
redox status of the myocardium, while excess reactive oxygen species (ROS) within the myocardium 
can inhibit calcium-ATP-hydrolysis coupling 151. Thus cardiac calcium homeostasis is highly sensitive to 
ROS 160–162.  
Calcium signaling itself is a major determinant of cardiac function and development of 
pathologies. Here it is SERCA, calcium/calcium-dependent pathways, phospholamban (PLB) and 
cardiac connexins that play a central role in the development, maintenance and propagation of 
cardiac contraction. Calcium transport for ECC is regulated by the RyR (on the SR membrane), SERCA-
2a, and NCX, where SERCA-2a provides roughly 60% of the total calcium  transport 163–165. The action 
of SERCA pumping calcium into and from the SR ensures that a 1000-fold calcium gradient is 
maintained across the SR 166. This is essential in providing the contractile machinery with the 
necessary calcium to initiate electrical propagation of the contractile stimulus and mechanical 
coupling, but to also reload the SR lumen with calcium for the next contraction.  
SERCA isoforms are found in a variety of tissue types, where SERCA-1a is expressed in fast-
twitch skeletal muscle, SERCA-1b during fetal development, SERCA-2a in slow-twitch skeletal muscle 
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and the myocardium, SERCA-2b in non-muscle and neuronal cells 167, and SERCA-3 in epithelial and 
endothelial cell types 168,169. SERCA activity is mediated via β-adrenergic stimulation, phosphorylation 
170,171, thyroid hormones 172 as well as insulin 172. PLB is a key regulator of SERCA activity. 
Phosphorylation of PLB occurs at 3 different sites mediated by a variety of proteins: at Ser16 by 
protein kinase A (PKA), at Thr17 by calcium/calmodulin dependent protein kinase II (CaMKII) and at 
Ser10 by protein kinase C (PKC). Phosphorylation at these sites causes a conformational change in PLB, 
causing it to dissociate from SERCA and relieve its inhibitory effect 163,170,171,173–184. Studies showed 
that PLB inhibition results in increased SERCA activity together with improved velocity of calcium 
uptake  and heart function 185–189. The SERCA:PLB ratio is also critical in determining cardiac 
contractility 177,182,183. Further, modulation of PLB within the context of the failing heart is beneficial as 
genetic modification of PLB (knockout) results in an improvement in SERCA and contractile 
parameters 190–192.  
Two major pathways regulate cardiac calcium homeostasis namely the calcium/calmodulin-
calcineurin-NFAT and the calcium/calmodulin-dependent kinases-MEF2 pathways that involve 
calcineurin, calmodulin, nuclear factor of activated T-cells 3 (NFAT3) and myocyte enhancing factor 2 
(MEF2) (reviewed in 163). Calcium binds directly to calmodulin causing a conformational change to 
phosphorylated and activated CaMKII 193. This in turn alters for the dephosphorylation of NFAT3 for 
transport into the nucleus, where it can activate cardiac genes associated with myocyte growth 194 
and hypertrophy. MEF2 is also a downstream transcriptional regulator of NFAT3 and basal levels of 
expression help to maintain cardiomyocyte homeostasis. PGC-1α expression also works in conjunction 
with MEF2 195 to promote mitochondrial biogenesis during cardiomyocyte growth.   
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 Alterations in calcium metabolism with HIV PIs have been investigated in human 195,196 and 
cell-based studies 197. For example, cultured HL-1 cardiomyocytes were treated with physiologically 
relevant doses of both Lopinavir and Ritonavir and assessed for electrical signal disturbances within 
ion channels197. PIs mediated the activation of the volume-sensitive chloride ion channel, important 
during the stress response (swelling) and mechanical force (stretching). Here the action potential 
duration was significantly shortened, together with altered mitochondrial membrane potential and 
increased mitochondrial ROS. These results indicate that PIs can have far reaching consequences on 
ionic and electrical homeostasis. Moreover, clinical data show that PI treatment prolonged the PR 
duration and QRS interval (ECG studies) of HIV-positive patients 195,196. Here PIs emerged as 
independent predictors of increased PR durations and thus ECG abnormalities 196. Similar studies have 
supported these findings 198–201, albeit inconsistently 202,203. If ion channels are disrupted, action 
potential propagation does not occur correctly and can result in an ionic imbalance and also leakage 
of critical ions e.g. calcium, sodium and potassium into cellular compartments and upset the electrical 
gradient across membranes. This can further manifest as pathological signaling between the SA node 
within the atria and the ventricles with the Purkinje and His fibres. Prolonged portions of the ECG 
indicate a slowing of conductance velocity and do not allow the myocardium to maintain a steady 
rhythm during contraction. The depletion of endoplasmic calcium stores can also trigger ER stress that 
may result in the accumulation of unfolded proteins and ER-induced apoptosis (reviewed in 204).  In 
fact, ER stress is a common mechanism for PI-induced side-effects, e.g. Lopinavir is a potent inducer 
of ER stress that occurs downstream of ROS-dependent c-Jun N-terminal kinase (JNK) activation 205.    
 Impulse propagation between cardiomyocytes is another key factor that is tightly regulated. 
Here junctions are necessary to transfer electrical signals and chemical messengers between adjacent 
myocytes 206. Such junctions are formed from two hemi-channels (connexons) and when two 
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neighboring gap junctions connect they become connexins. Connexins are named according to size 
and differentially distributed within the myocardium, e.g. connexin 43 (Cx43) is the most abundant 
207–211. Cx43 is also expressed in rat cardiac mitochondria, implicating mitochondrial biogenesis and 
ionic homeostasis in pathological alterations in Cx43 expression (Fig. 8).  
When further elucidating connexin function, data revealed that the heart has a “conductance 
reserve”. While gene knockout studies of either Cx40 or Cx43 do not always result in loss of function 
208,212–217, transgenic in vivo models of connexin expression present with ventricular arrhythmias and 
atrial fibrillation 218–224. Connexins have a relatively short half-life and undergo rapid turnover and 
recycling via the ER-associated degradation (ERAD) pathway with the assistance of proteasomal 
degradation 225–228. Connexin phosphorylation results in activation and priming for ERAD 267, while 
connexins also regulate gating 268. Studies found that when endocytosis of Cx43 for ERAD was 
inhibited this increased ubiquitinated Cx43 levels indicating that the proteasomal pathway is involved 
in Cx43 turnover and degradation 231–234. To the best of our knowledge, no studies have been 
published regarding Cx43 biology and PI treatment.   
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Figure 8. Connexin biology and alterations in expression. Left panel: ions and proteins such as 
calcium and cAMP and depolarizing stimuli in the form of action potentials are exchanged between 
neighboring myocytes through gap junctions. Calcium and depolarization can further ensure myocyte 
contraction and cAMP mediates energy producing pathways. Right: connexin expression for the 
formation of gap junctions is critical. Any alteration in connexin expression (genetically or via altered 
turnover through the proteasome) can create pathologies associated with ventricular fibrillation, 
arrhythmia and irregular heart rate. Further, ion channels and ionic gradients malfunction and lead to 
misfiring and incorrect propagation of electrical signals within the heart.  
 
 
 
 
 
   
 
Stellenbosch University  http://scholar.sun.ac.za
55 
 
HIV PIs and energy homeostasis: role of PGC-1α 
As previously mentioned, the dephosphorylation of NFAT3 and nuclear translocation promotes 
downstream gene transcription pathways involved in cardiomyocytes growth and mitochondrial 
biogenesis 194. PGC-1α is a pivotal transcription modulator that regulates the transcription of 
mitochondrial and hypertrophic genes, and replication of mitochondrial DNA (mtDNA) and deserves 
further attention. 
Regulators associated with PGC-1α include the mitogen-activated protein kinases (MAPK) 235–
237, β-adrenergic/cyclic AMP 238, nitric oxide 239, AMP-activated protein kinase (AMPK) cascade 240, 
calcium/calmodulin/calcineurin pathway 241, peroxisome proliferator activator receptor gamma 
(PPARγ)242,243 , thyroid hormones 244 and MEF2245. These regulators bind to the promoter region to 
activate transcription of PGC-1α, and may also bind to PGC-1α itself 246. PGC-1α possesses an RNA 
processing domain and adaptor/scaffold ability to remodel chromatin as it is unable to bind directly to 
its DNA target 247–249. Here the regulators directly interact with PGC-1α to activate downstream 
transcription factors such as nuclear respiratory actor 1 (NRF-1) 250 to promote the transcription of 
mitochondrial genes such as mitochondrial transcription factor A (mtTFA) 251. mtTFA is transported to 
the mitochondrion  from the nucleus and subsequently activates the transcription of ETC components 
such as the COX and ATPase subunits 252–254 . Thus NRFs together with PGC-1α ensure the activation 
of mitochondrial biogenesis 252,253,255,256 (Fig. 9).  
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Figure 9. The PGC-1α pathway. Stressors such as exercise, hibernation or infection trigger a cascade 
of energy-sensing pathways. Here ATP levels, AMPK and calcium interlink and initiate the 
translocation of transcription factors to and within the nucleus, including dephosphorylated NFAT3. 
These transcription factors (PGC-1α, AMPK, NRF1, NFAT3, MEF2, PPARγ) bind to the promoter region 
of the PGC-1α gene to transcribe components essential for myocyte growth and hypertrophy. In 
parallel, NRF1 binds to the promoter region of the mtTFA gene to initiate the transcription and 
translocation of mtTFA to the mitochondrion – ensuring an increase in mitochondrial biogenesis, 
electron transport chain components and redox enzymes. These processes ensure that myocyte 
growth and energy capacity are elevated especially in the case of exercise and fiber-type switching. 
AMP – adenosine monophosphate, ATP – adenosine triphosphate, AMPK – AMP kinase, CaMKII – 
calmodulin kinase II, ETC – electron transport chain, NFAT3 – nuclear factor of activated T-cells 3, 
NRF1 – nuclear respiratory factor 1, MEF2 – myocyte enhancing factor 2, mtTFA – mitochondrial 
transcription factor A, PPARγ – peroxisome proliferator-activator gamma, PGC-1α – PPARγ cofactor 
1α. 
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Mitochondrial biogenesis and energy metabolism are critical in meeting and maintaining 
intracellular energy requirements. Thus transcription of mitochondrial DNA and biogenesis needs to 
be tightly regulated to ensure optimal energetics. Studies overexpressing PGC-1α demonstrated 
increased mitochondrial number in cardiomyocytes 257, and enhanced mitochondrial biogenesis, 
respiratory rates, fuel substrate uptake and utilization 250,257,258. Further, deletions of PGC-1α highlight 
its essential role in mitochondrial energetics 259. In addition, decreased PGC-1α expression is a 
common feature of heart failure during pathological cardiac hypertrophy 260–262.   Current research 
involving PIs and the PGC-1α is sorely lacking, with a single study reporting that the PI Indinavir 
decreased mitochondrial respiration and ATP production together with attenuated expression of 
COX2 and COX4 263. Therefore further investigation is hastily required. Finally, prolonged PGC-1α 
overexpression caused mitochondrial biogenesis and cardiomyopathy that accompanies 
mitochondrial ultrastructural changes 257,264, implicating an elevated future risk for adaptive 
responses to become pathological. These results implicate PGC-1α in mitochondrial perturbations 
associated with PI treatment. 
Oxidative stress plays a significant role in affecting the PGC-1α pathway. As noted by Richter et 
al. (1988) 265 and Ames et al. (1993) 266, human mtDNA is more susceptible to mutations and oxidative 
damage. Subsequently, mtDNA copy number increases with ageing but this does not alleviate the age-
related decline in mitochondrial respiration 267. However, PGC-1α combats this susceptibility in 
healthy individuals and early stages of ageing by regulating production of mitochondrial anti-oxidant 
enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase and thioredoxin 
259,266,268 . Thus the anti-oxidant role of PGC-1α is crucial to ensure cardiac mitochondrial and 
contractile functioning. Therefore, perturbations in the PGC-1 α pathway can have serious 
consequences on energy metabolism, mitochondrial health and cardiac contractility.  
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These data therefore shed light onto the potential mechanisms of PI-induced cardiac 
dysfunction and metabolic alterations, with the UPS playing a central role in the downstream effects. 
Our unifying hypothesis centres on the UPS and the detrimental downstream effects of PIs (Fig. 10). 
Here PIs competitively bind and decrease the UPS, thus attenuating degradation of key proteins such 
as the SREBPs, SERCA and the connexins. Subsequently, we propose that SREBPs remain bound to 
their target gene promoters and continue activating transcription of enzymes involved in lipid and 
cholesterol synthesis, thereby creating a hyperlipidemic and hypercholesterolemic environment 
within tissues and the blood. We further propose that SERCA activity will also be enhanced by the 
lowered UPS, and although it is tightly regulated by PLB, increased calcium transport back into the SR 
lumen may deprive the contractile machinery of the necessary calcium for contraction but also 
removal. Calcium supply is therefore disrupted and can have a knock-on effect on other calcium 
channels within the myocardium. Further, ionic imbalances may lead to a positive-feedback 
mechanism between calcium and the mitochondrial proton gradient, eventually contributing to an 
abnormal ionic status within the myocardium. Since connexins rely on frequent turnover, UPS 
inhibition may lead to over-accumulation of connexins thus disrupting normal electrical conductance. 
Here enhanced conduction velocity may develop into arrhythmias and irregular heart rate, ultimately 
resulting in contractile dysfunction and CVD in the long-term.  
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Figure 10. Molecular hypothesis for PIs and their detrimental effects on heart function. The unifying 
hypothesis encompasses the inhibition of the UPS as a central mechanism to PI-induced cardiac 
dysfunction. Over-accumulation of proteins that would otherwise be degraded, such as SREBP, SERCA 
and Cx43, have downstream consequences that impair the contractile machinery and metabolic 
processes. Ultimately, an atherosclerotic phenotype can develop and contractile dysfunction may 
occur. 19S/20S – proteasomal subunits, ACC – acetyl coa carboxylase, Ca+2 – calcium, Cx43 – connexin 
43, DM – diabetes mellitus, ETC – electron transport chain, FAS – fatty acid synthase, GPAM – glycerol-
3-phosphate-acyltransferase 1 [mitochondrial], MetS – metabolic syndrome, PGC-1α – peroxisome 
proliferator activator gamma coactivator 1 alpha, PI – protease inhibitor, SERCA – sarcoplasmic 
endoplasmic reticulum ATPase, SR – sarcoplasmic reticulum, SRE – sterol response element, SREBP – 
sterol regulatory element binding protein. 
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PIs and cardiac dysfunction within the context of oxidative stress 
Impaired redox status within the myocardium can be associated with negative outcomes in terms of 
functionality and contractility. As mentioned previously, mitochondria and related redox enzymes 
play a central role in the development of PI-related cardiomyopathies. However, the question still 
remains how and why PIs interfere with cardiac redox signaling ultimately manifesting in contractile 
pathologies.  
The link between PI usage and increased ROS production is well established by several human 
269, animal 270–273  and cell-based studies 274–278.  These include numerous cell and tissue types, i.e. 
macrophages 276, cardiomyocytes 197, endothelial cells 279,280, pancreatic β–cells 270,272, intestinal 
epithelial cells 281, pulmonary aortic endothelial cells 282, human skeletal muscle cells 273, adipocytes 
274,283, hippocampal neurons 284, porcine arteries 277,285, and aortas in an atherogenic mouse model 
277,279,285. All these studies point towards an increase in the production of oxidant molecules and 
activation of pro-oxidant pathways that ultimately results in elevated oxidant stress within cells and 
surrounding tissue. 
The main intracellular sources of ROS production include the mitochondrial ETC 286,287, NADPH 
oxidases (NOX) 288,289, xanthine oxidase 290,291, and cytochrome P450 292,293.  However, the majority of 
ROS production originates from mitochondria, generated by respiratory chain complexes I and III 
located within the IMM 294.  Additional sources of mitochondrial ROS include matrix dehydrogenases 
and mono-amine oxidase in the OMM [reviewed in 295]. Electrons leaking from mitochondrial 
respiratory complexes I and III are able to bind to molecular oxygen (O2) to form superoxide (O2
• -).   
Intriguingly, these complexes generate two distinct O2
• - pools.  Complex I releases O2
• - from the IMM 
(impermeable to superoxide) into the matrix 287,294.  Superoxide found within the mitochondrial 
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matrix can be converted to hydrogen peroxide (H2O2) by manganese superoxide dismutase (MnSOD), 
i.e. 2O2
• - + 2H+ → O2 + H2O2.   However, complex III can release O2
• - into both the mitochondrial 
matrix and the IMM space, and since the OMM is permeable to O2
• - it can translocate into the 
cytosol.  Here copper/zinc superoxide dismutase (Cu/Zn SOD) converts O2
• - to H2O2 within the cytosol 
and the inter-mitochondrial membrane space.  Thereafter H2O2 can be removed by catalase or GPx 
296,297.  However, in the mitochondrial matrix GPx is the main regulator of H2O2 with catalase playing 
an insignificant role 298.    
Physiologic ROS levels play a crucial role in regulating intracellular signaling pathways and 
gene expression, referred to as ‘’redox signaling’’ 299,300. Here NOXs are key modulators that generate 
highly regulated amounts of O2
• - by electron transfer from NADPH to molecular oxygen 301–304. 
However, excess and damaging reactive species may be generated by increased activation of reactive 
species-generating systems and/or decreased capacity of anti-oxidant defense systems. For example, 
if O2
• - and H2O2 are not appropriately detoxified then H2O2 can be converted to the highly reactive 
hydroxyl anion (OH•) by non-enzymatic pathways, e.g. the Fenton reaction 305 while O2
• - can react 
with nitric oxide to form peroxynitrite (ONOO-) 305.  
What are the origins of PI-induced ROS?   The precise source(s) of ROS remain unclear 
although most studies suggest a mitochondrial origin 278.  However, Ritonavir treatment of porcine 
carotid arteries increased O2
• - production by NOX indicating the presence of extra-mitochondrial ROS 
277.  The exact mechanisms and sequence of events whereby PI treatment triggers intracellular ROS 
production are not well understood.  Further, mitochondrial membrane biology is also affected by PI 
therapy. For example, PIs can increase mitochondrial membrane potential depolarization in HL-1 
myocytes 197 that would be expected to impair mitochondrial respiration and ATP generating capacity.  
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In agreement, others found higher mitochondrial membrane depolarization together with an 
impairment of cellular oxygen consumption 306. We are of the opinion that activation of UCPs may 
help mediate such effects, e.g. Nelfinavir treatment elevated UCP2 levels in pancreatic β–cells 272.  
Impairment of mitochondrial function may also result due to mtDNA damage and fragmentation of 
the mitochondrial network 307,308.  
In light of this we propose a unified model based on the current literature that features a wide 
variety of experimental models and cell types (Fig. 11). However, there is limited information of PI-
mediated effects on the heart and further studies are required to ascertain whether this model 
applies to the mammalian heart.   In the first instance we propose that PIs exert direct effects on 
enzymes that regulate the balance between ROS generation and detoxification.  For example, 
Nelfinavir treatment of rat pancreatic cells decreased intracellular Cu/ZnSOD (but not MnSOD) 
activity, thereby elevating cytosolic ROS generation 272.  In agreement, glutathione levels were 
attenuated suggesting decreased GPx activity, although this was not determined.   Diminished 
Cu/ZnSOD and GPx activities will be expected to increase ROS levels within the cytosol and the inter-
mitochondrial membrane space.   Cytosolic ROS levels may be further enhanced by leakage of 
reactive species across the porous OMM.  We further propose that intracellular ROS thus generated 
(cytosolic and inter-membrane space) are able to inhibit respiratory chain complexes located within 
the IMM [reviewed in 309].   
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Figure 11. PIs and oxidative stress. HIV PIs elicit a variety of effects at the cellular level. For example, 
PIs increase NADPH oxidase, and decrease Cu/ZnSOD and COX4 gene expression. This would be 
expected to increase and decrease NADPH oxidase and Cu/ZnSOD activities, respectively.  Moreover, 
lower COX4 levels may impair mitochondrial respiratory capacity. PIs can also directly affect enzyme 
activities of Cu/Zn SOD and NADPH oxidase in the cytosol, resulting in ROS generation with damaging 
intracellular effects. Mitochondrial Cu/ZnSOD activity is also downregulated and thus increases the 
generation of ROS within the intermembrane space. Higher ROS levels may inhibit complexes I and III 
of the ETC, thereby increasing matrix and cytosolic ROS levels. In this manner, mitochondria are also 
damaged. O2
•- superoxide free radical, OH• - hydroxyl radical, H2O2 – hydrogen peroxide, ONOO
- - 
peroxynitrite, Cu/Zn SOD – copper/zinc superoxide dismutase, COX4: cytochrome c oxidase 4, NADPH - 
nicotinamide adenine dinucleotide phosphate hydrogen, PI – protease inhibitor, ROS: reactive oxygen 
species. 
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Thus a vicious cycle is created whereby decreased ETC activity will generate more reactive 
species thereby further elevating intracellular ROS levels, with damaging consequences. Moreover, 
greater superoxide production from complex I will elevate mitochondrial ROS levels (confined within 
the matrix) with detrimental effects.  PI-induced increases in NOX activity will further exacerbate 
these effects by generating even higher O2
• - levels.  We believe that it is unlikely that PIs directly 
inhibit the respiratory chain complexes since there is no evidence, as far as we are aware, supporting 
PI localization within the mitochondrial matrix.  In agreement, Vernochet et al. (2005) 310 tracked 
intracellular localization of PIs by fluorescent tagging and found no localization within the nucleus.  
They did not report on the mitochondrial localization of PIs, but its lack within the nucleus suggests it 
is unlikely that it entered the mitochondrial matrix. However, further studies are required to ascertain 
whether PIs are able to enter the matrix and exert direct effects on myocardial ETC complexes.   
At another level, PIs may also exert transcriptional effects thereby altering expression of ROS 
generating/detoxifying enzymes and increasing intracellular reactive species levels. For example, 
Ritonavir-treated cells exhibited elevated mRNA levels of NOX subunits p22phox, p40phox, p47phox, and 
p67phox 276.  NOX is a multi-subunit complex and its enzymatic activity depends on both catalytic and 
regulatory subunits (e.g. p22, p40, p47, and p67) 293.  Ritonavir treatment also increased O2
• - levels, 
thus suggesting higher NOX activity.   
Investigation of the NOX pathway further supports the role of PIs in oxidative stress. Chai and 
colleagues (2010) 311 investigated PI treatment in porcine coronary arteries and found decreased 
endothelial nitric oxide synthase (eNOS) expression with Ritonavir therapy, together with increased 
nitric oxide levels. Functional studies established decreased endothelium-dependent vasorelaxation 
thus confirming these findings 275,277,278,285,312. Furthermore, HIV infection itself also plays a role in 
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altering intracellular oxidant status, i.e. a transgenic rodent model expressing HIV proteins Tat, gp120 
and Nef revealed detrimental perturbations in the cysteine and glutathione pathways with additional 
changes to cardiac morphological parameters 313.  
PI treatment can also attenuate expression of anti-oxidant modulators.  For example, 
Nelfinavir decreased Cu/ZnSOD, but not MnSOD, peptide levels in rat pancreatic β–cells, associated 
with greater enzyme activity and higher ROS production 272. These data suggest that PIs more likely 
exert transcriptional effects on nuclear-encoded compared to mitochondrial-encoded DNA. However, 
adipocytes exposed to PIs displayed reduced gene expression of both nuclear-encoded COX4, and 
mitochondrial-encoded COX2 263.  Decreased COX levels may impair complex IV capacity (i.e. 
accepting electrons to reduce molecular oxygen to water), increase electron leakage within ETC 
complexes and thereby elevate O2
• - production.  Nonetheless, it remains uncertain whether PIs exert 
direct or indirect effect on the redox system, as the UPS and PGC-1α also play critical roles to play in 
regulating intracellular redox homeostasis. Together these studies suggest that PIs increase ROS by 
both direct (at enzyme activity level) and indirect means (altering gene expression, activating the PGC-
1α pathway), thereby causing damaging effects within the cytosol and the mitochondrion. This in turn 
can result in damaging effects within the cytosol and the mitochondrion, i.e. decreased mitochondrial 
respiratory capacity, increased uncoupling of oxidative phosphorylation, lower mitochondrial ATP 
generation and greater activation of cell death pathways.  Together this will increase the heart’s 
susceptibility to stress, e.g. myocardial ischemia.   
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Conclusion 
 
In conclusion, this review demonstrates that early changes triggered by PI treatment include 
increased body weight and lipid levels that resemble a pre-atherogenic profile and the MetS. Such 
changes are accompanied by an increased transcription (largely SREBP-mediated) of target genes for 
cholesterol and lipid metabolism.  Furthermore, long-term PI usage can place the heart at a 
disadvantage from a metabolic and contractile point of view. Mitochondrial metabolism can be 
impaired and oxidant generation/removal systems together with the UPS may represent useful 
starting points for the molecular alterations associated with PIs that ultimately create a pro-oxidant 
status within the cell.  Though this may represent an adaptive response initially, in the long-term it is 
unable to counteract strain on the mitochondrial energetic system and prevent contractile 
dysfunction.  The UPS is also a downstream target of PIs and ROS, although there may be cross-talk 
between these systems.  Moreover, HIV PIs may directly impair UPS in the heart. Dysfunctional UPS 
may also trigger alterations in ionic channels and interfere with electrical signaling in the myocardium.  
Thus while PIs substantially improve life expectancy and quality of life in HIV-positive patients, its 
long-term usage can initiate toxic side-effects that may lead to cardio-metabolic dysfunction. From a 
philosophical view point, it is therefore imperative that clinicians be mindful of the benefit-harm 
paradigm of ARVs within the clinical setting.  Studies investigating the molecular mechanisms 
whereby HAART (and specifically PIs) can elicit such side-effects are therefore of the utmost 
importance. 
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Introduction 
 
PIs form an integral part of HAART and side effects include the development of dyslipidemia, i.e. 
increased production of plasma TGs and lipids, together with an adverse cholesterol profile 1 as well 
as peripheral and central fat hypertrophy 2. Together such metabolic derangements elicit 
inflammation, stress the myocardium 3,4, and may potentially predict the onset of IR and cardiac 
dysfunction 5,6 .  
The most common side effects experienced with Lopinavir/Ritonavir usage are diarrhea, 
nausea, and lipid abnormalities (elevated cholesterol and TG) 7.  Moreover, metabolic changes 
associated with PI usage resemble the MetS, a combination of risk factors that predispose to future 
onset of T2DM and CVD 8.  In support, human 6,9–14, animal 15–17 and cell-based 18–21 studies 
demonstrate that increased plasma cholesterol and TG levels, and the development of lipodystrophy 
and IR are the most common metabolic perturbations found with PI treatment.   
In the setting of lipodystrophy, an imbalance in fat partitioning occurs, with lipoatrophy 
occurring at the extremities and accumulation of fatty tissue more centrally especially at 
subcutaneous sites such as the waist, hips and neck. Such an accumulation of lipids may predispose 
an individual to dyslipidemia. Further, the increased burden of lipodystrophy with HIV infection can 
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alter FA metabolism and ensure that abnormal lipid levels become indicative of the MetS phenotype. 
Such alterations may or may not be accompanied by anthropometric changes, e.g. body weight, waist 
circumference and BMI 22. However, dyslipidemia and MetS can co-manifest with anthropometric 
alterations, especially for PI administration regimens longer than 12 months 23–27. Lastly, PI-mediated 
perturbations to glucose metabolism can also occur. For example, PIs can impair glucose tolerance as 
well as multiple facets of glucose metabolism, ultimately resulting in IR 9,28,29.  
These data therefore indicate that PIs have far reaching consequences on metabolism. 
Moreover, PIs act early at the molecular level, e.g. activating key metabolic pathways (mitochondrial 
impairment, oxidative stress), thereby initiating a cascade of detrimental alterations contributing to 
the development and presentation of dyslipidemia, lipodystrophy and weight gain. However, the 
precise molecular mechanisms defining PI-mediated cardio-metabolic changes remain less well 
understood. In light of this, we set out to first establish a rat model of chronic PI utilization as a 
platform to further investigate this intriguing system. For this study we hypothesize that PIs 
pathologically alter lipid metabolism and glucose metabolism. Here an attempt was made to 
investigate this hypothesis in the context of varying dietary intake (normal versus high fat diets) to try 
and simulate realities faced by individuals receiving HAART. 
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Materials & Methods 
 
Animal model 
The use of animals and procedures were reviewed and approved by the Animal Research 
Ethics Committee of the Faculty of Natural Sciences of Stellenbosch University (application numbers 
2006B02006, 11NF_REY01, SU_ACUM11_00006, and related amendments). This study adheres to the 
guidelines set out by the National Institutes of Health’s Guide for the Care and Use of Laboratory 
Animals and performed with the approval of the Animal Ethics Committee of Stellenbosch University 
(South Africa). Male Wistar rats were housed (maximum 4 animals per cage) in the Faculty’s animal 
facility and a standard light/dark cycle (12 h-12 h) maintained throughout the duration of the study. 
We ensured animals had access to food and water ad libitum; with body weight, food consumption 
and general health monitored on a daily basis. Rats were acclimatized for 14 days (starting at day -14) 
to their housing conditions and the investigator, after which experiments were initiated. Interventions 
commenced on the first day (Day 0) when rats exhibited weights of 160-220 grams (g). A total of 8 
rats were used per experimental group and as follows: sham, vehicle, PI-treated, high fat (HF) and PI-
treated animals on a high fat diet (PI+HF) (deviations explained for individual experiments further 
below). 
Dietary intervention 
 Animals were fed either low fat chow (D12450B, Research Diets, New Brunswick, NJ) with 10% 
kilocalories as fat, or HF chow with 45% kilocalories fat (D12451, Research Diets). The dietary 
constituents were as follow (% kcal): Low fat chow – fat (10), protein (20), carbohydrates (70); and 
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high fat chow – fat (45), protein (20), and carbohydrates (35). All animals were provided with the low 
fat chow during the acclimatization period (Day -14 to Day 0) and thereafter received the low or HF 
diet, respectively, for a total of 8 weeks. This will be indicated in the results section of this chapter.  
Drug administration 
 Lopinavir/Ritonavir (KaletraTM, Abbott Laboratories, Abbot Park IL) was crushed and dissolved 
in a 1% ethanol (vehicle) solution at human steady-state plasma concentration (7.1 ± 2.9 µg/mL), 
sterile filtered and injected into a mini-osmotic pump (Alzet, Cupertino CA). Male Wistar rats (160-220 
g) received either: mock surgery (sham), vehicle-, or PI-containing pump for a total of 8 weeks (n=8 
per group).  Here we attempted to simulate a relatively early stage of PI treatment, i.e. if the average 
lifespan of 2-3 years is taken for Wistar rats then 8 weeks translates to  6% of its total lifespan.  This 
would correspond to  2-3 years of PI treatment for a 30 year-old started on HAART treatment and 
with a life expectancy of  60-70 years.   
Briefly, rats were anesthetized with isofluorane in oxygen (5% for induction, 1.5-3% for 
maintenance) after a 4-hour (hr) fasting period with the incision site shaved and sterilized below the 
right shoulder blade. A 1-2 cm incision was made into the skin and a pocket created with a hemostat 
to place the pump subscapular. After the pump was inserted the wound was closed with 2-3 sutures, 
wiped with iodine and intra-muscular painkiller (buprenorphine, 0.05 mg/kg) administered before the 
rats awoke from anesthesia. Rats recovered in individual cages for the first 6 hours (hrs) with access 
to food and water ad libitum to monitor wound healing, and placed back with litter mates within 24 
hrs of surgery upon complete wound closure.    
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Body weight and food consumption 
 Weight gain was measured at weekly intervals throughout the 8-week treatment period. Food 
consumption was assessed daily and total intake was then determined and averaged per rat per cage.  
Blood lipid profile and HOMA-IR assessment 
In separate experiments, serum and tissue metabolite levels were evaluated following PI 
treatment. Due to financial constraints we did not continue with the HF feeding regimen and only 
assessed blood lipid profile and homeostatic model of assessment of insulin resistance (HOMA-IR) in 
PI-treated animals and their controls for the remainder of the study. After 8 weeks (4-7 days before 
termination of treatment period) rats underwent a 12-18 hr overnight fast where after blood was 
collected from the jugular vein, serum isolated and analyzed for: total and low-density lipoprotein 
(LDL) cholesterol, FFA and TG levels (NHLS, Tygerberg Hospital, South Africa).  Weekly fasting glucose 
measurements via tail prick were also determined using a glucometer (AccutrendTM glucometer, 
Roche Diagnostics, IN). We also evaluated the HOMA-IR – here serum insulin and glucose levels were 
also determined (PathCare Laboratory, Stellenbosch, South Africa).  The HOMA-IR was calculated as 
follows: (glucose [mg/dL] x fasting insulin [μU/mL] / 2.43) and the equation used in accordance with 
the guidelines for HOMA-IR assessment in rodents 30.  
Cytokine profile 
 Serum was further analyzed after 8 weeks of PI therapy (no dietary intervention, see “Blood 
Lipid Profile” above) for cytokines associated with inflammation such as tumor-necrosis factor alpha 
(TNFα) and interleukin 6 (IL-6). The enzyme-linked immunosorbent assay (ELISA) technique was 
employed for TNFα (TNFα ELISA Ready-SET-Go!, eBioscience, San Diego CA) and IL-6 (Legend Max™ 
Rat IL-6 ELISA, BioLegend, San Diego CA). Both cytokines were assessed according to the 
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manufacturer’s instructions. Briefly, a clear 96-well microtiter plate was pre-coated with primary 
antibody raised against the rat-specific immunogen of TNFα or IL-6. Serum was prepared according to 
the manufacturer’s instructions with the necessary buffers supplied in the kit and diluted accordingly. 
A standard curve of known concentrations of either cytokine was made and the serum samples 
aliquoted into the remaining wells as the unknowns. Through various steps of incubation and 
washing, cytokines present in the serum samples were immunocaptured in the wells, excess antibody 
and serum components washed off, non-specific binding sites blocked, and secondary antibody 
conjugated to Avidin-HRP to detect cytokines via a color-change reaction. A colorimetric plate reader 
(Cecil CE2021 spectrophotometer, Cecil Instruments, Cambridge, UK) measured absorbance for both 
cytokines at 450 nm, and concentrations extrapolated from the standard curve were expressed as 
pg/mL.  
Statistical analyses 
One-way analysis of variance (ANOVA) was utilized for all experiments with a Bonferroni post-
hoc test to compare variation between all the groups. Body weight over the 8-week treatment period 
was analyzed via two-way ANOVA. Statistical significance was considered when p<0.05, and data 
expressed as mean ± standard error of the mean (SEM).  
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Results 
 
Since PI therapy has negative side effects that resemble the MetS, the aim of this study was to 
establish and characterize a novel rodent model with chronic PI treatment and further understanding 
of the mechanisms underlying such changes. Our first aim included assessment of weight during the 
8-week treatment period as an indication of possible lipodystrophy – body fat redistribution – which 
could present as weight gain. Indeed, PI-treated rats exhibited weight gain (467 ± 18.1 vs. sham 385 ± 
17.2 g, p< 0.001; and vs. vehicle 400 ± 18.1 g, p<0.001 (Fig. 1A). As expected the HF diet group also 
experienced significant weight gain in comparison to the control groups. However, neither this group 
nor the combination of a HF diet and PI treatment displayed differences in weight gain when 
compared to PI treatment alone (p>0.05) (Fig. 1B). Nonetheless, all three treatment groups i.e. PI, HF 
and PI+HF displayed greater weights at 8 weeks than sham and vehicle (Fig. 2A), though the 
percentage change was only significant for the HF diet group.  
 
Figure 1. Body weight changes in response to 8 weeks PI treatment (n=16). A) PI-treated groups; and 
B) high fat treated groups. Data presented as mean ± SEM. **p<0.01 and ***p<0.001 vs. sham, 
##p<0.01 and ###p<0.001 vs. vehicle. HF – high fat, PI – protease inhibitor. 
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Figure 2. Terminal weight and percentage change due to PI and high fat dietary intervention (n=≥8). 
Final weights were measured on the day of killing after 8 weeks chronic PI treatment, and the change 
in weight is calculated as the percentage gain in weight normalized to the sham group. A) Final 
weight; and B) Percentage change in weight. Data presented as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001 vs. sham; #p<0.05, ###p<0.001 vs. vehicle. HF – high fat, PI – protease inhibitor.  
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Food consumption reveals an interesting finding. PI-treated rats and the HF diet animals 
displayed higher food consumption (Fig. 3) versus controls (894 ± 17.8 g PI and 913 ± 64.4 g HF vs. 
sham and vehicle, p<0.05). Intriguingly, when PIs were co-administered with a HF diet, food 
consumption returned to baseline values (673 ± 35.2 vs. sham 707 ± 14.3 g, p>0.05; and vs. vehicle 
717 ± 13.0 g, p>0.05).   
 
Figure 3. Total food consumed during 8 weeks of PI and high fat dietary intervention (n≥8). Food 
consumption was calculated as the average total amount of food consumed per rat for the duration 
of the intervention and averaged to the number of animals per cage. Data presented as mean ± SEM. 
*p<0.05 vs. sham, #p<0.05 vs. vehicle, $p<0.05 vs. PI, ψp<0.05 vs. HF. HF – high fat, PI – protease 
inhibitor. 
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Due to the nature of this study, the next set of experiments were carried out in a separate 
group of animals, and as previously mentioned, financial constraints led us to exclude the HF diet 
from subsequent analyses. Therefore, only sham, vehicle and PI-treated animals are utilized from this 
stage onwards. Since glucose abnormalities e.g. IR/T2DM are linked with PIs, we next assessed a) 
fasting glucose levels during 8 weeks of PI therapy with HOMA-IR,  and b) an intra-peritoneal glucose 
tolerance test (ipGTT). However, due to technical difficulties the ipGTT was unsuccessful (Fig. 4). 
Weekly glucose measures revealed that none of the experimental groups experienced any significant 
changes to glucose levels that would indicate abnormalities (p>0.05 for all time points) (Fig. 5), and 
the HOMA-IR data confirmed this (p>0.05) (Fig. 6). 
 
 
Figure 4. Intra-peritoneal glucose tolerance test (ipGTT) in response to chronic PI therapy (n=8). 
After an overnight fast, rats were injected i.p. with 2 mg/kg glucose and assessed for glucose response 
over 60 minutes. Data presented as mean ± SEM. PI – protease inhibitor. 
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Figure 5. Weekly fasting glucose levels during 8 weeks of PI therapy (n=8). Weekly fasting glucose 
levels determined (commercial glucometer) for an 8-week period. A) PI-treatment; and B) HF diet. 
Data presented as mean ± SEM. HF – high fat, PI – protease inhibitor. 
 
 
 
Figure 6. HOMA-IR and other parameters of glucose metabolism (n=8). PI treatment elicited no 
significant alterations in glucose metabolism parameters after 8 weeks of PI treatment versus 
controls. Data presented as mean ± SEM. HOMA-IR – homeostatic model of assessment for insulin 
resistance, PI – protease inhibitor. 
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Next, fasting serum levels for FFAs; TGs, total cholesterol, and LDL-cholesterol were assessed, 
but did not significantly differ with PI treatment (Fig. 7).  However, PI treatment increased serum LDL-
cholesterol levels to 0.433 ± 0.021 mM vs. sham 0.216 ± 0.005 mM, p<0.05; and vs. vehicle 0.216 ± 
0.005 mM, p<0.05). 
 
 
Figure 7. Lipid profile in response to 8 weeks PI treatment (n=8). Data presented as mean ± SEM. 
*p<0.05 vs. sham, #p<0.05 vs. vehicle. LDL – low-density lipoprotein, PI – protease inhibitor. 
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Cytokine profiles were also assessed in response to chronic PI treatment. However, since both 
serum TNFα and IL-6 levels fell below the detection limit of the ELISA kits (TNFα: 16 pg/mL and IL-6: 
5.3 pg/mL) no conclusions could be drawn from this particular experiment (Fig. 8). 
 
 
Figure 8. Cytokine profile of TNFα and IL-6 in response to PI therapy (n=8). Both cytokines were not 
detectable within physiologically relevant concentrations as determined by the ELISA method in 
response to PI treatment. ELISA – enzyme-linked immune-sorbent assay, IL-6 – interleukin 6, PI – 
protease inhibitor, TNF – tumor necrosis factor alpha. 
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Discussion 
 
Although HAART markedly improves the quality of life and prognosis of HIV-infected individuals, it 
may elicit cardio-metabolic side effects in the long-term. Since molecular mechanisms underlying this 
process are poorly understood, early metabolic changes were evaluated in our unique rat model of PI 
treatment. The main findings of this study are 1) PI-treated rats exhibit increased weight gain; and 2) 
lipid abnormalities at this early time point were present.  
 
PI-treated rats exhibit increased weight gain 
The availability of a PI dose at a constant rate throughout the study, as opposed to fluctuating 
plasma drug concentrations due to daily administration, highlights a novel approach to this study. We 
believe this approach may be useful to elucidate molecular and functional effects of PI treatment, and 
may unlock innovative therapeutic interventions to better deal with the HIV/AIDS pandemic, 
especially within a chronic setting. The data reveal that both PI treatment and the HF diet increased 
weight gain in our model, but its combination did not result in an additive effect. We are of the 
opinion; however, that the moderate obese phenotype found in our experimental model with PI 
treatment may be representative of broader society as global obesity has risen in the last decades in 
parallel to the HIV pandemic.    
 The food consumption data yielded interesting results, i.e. increased with PI treatment and 
decreased with additional high fat feeding. It is unclear why this is the case. However, a relatively 
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crude measure to determine food intake was employed. It is possible that one or two animals may 
have consumed much more, or less food, thereby skewing the data. Alternatively, we speculate that 
differences in nutritional intake may be due to altered leptin and/or ghrelin levels that usually act as 
satiety signals. A variety of in vitro 31,32, in vivo31,33,34 and human24,35 studies have shown decreased 
leptin levels to be linked with the development of lipodystrophy 36, glucose intolerance (at central and 
peripheral adipose and skeletal depots), oxidative stress 31,33,34, lipid derangements and inversely 
correlated to chronic inflammation 10,31. Leptin, neuropeptide Y and ghrelin are well-known regulators 
of dietary intake 37. We propose that PI treatment in our model may perturb circulating leptin and/or 
ghrelin levels thereby interfering with dietary intake, and subsequently weight gain. These interesting 
possibilities require further investigation.  
Previous studies demonstrated that a significant proportion of patients receiving HAART 
patients develop impaired glucose tolerance, IR and T2DM 5,6 but at a later stage in treatment 
duration.  Here the data revealed that PI-treated rats displayed weight gain together with elevated 
serum LDL-cholesterol, identifying perturbed lipid metabolism as a relatively early occurrence.  
Although not focusing on initial PI-mediated changes, earlier research work also reported that lipid 
derangements are one of the commonest side-effects triggered by Lopinavir/Ritonavir usage 7.   
Moreover, our study shows that the onset of IR follows at a later stage in the progression of cardio-
metabolic dysfunction following PI treatment.  How exactly does PI treatment induce the changes in 
lipid metabolism here observed?   The mechanisms underlying higher food consumption with PI 
exposure are unclear and hence form part of our ongoing investigations.    
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Measurements of glucose and insulin metabolism 
Fasting serum glucose levels did not significantly differ for the various experimental groups. 
We were not completely surprised since it is more likely to manifest after long-term PI therapy or HF 
intake, e.g. rats on a HF diet for 12 or more weeks 38 and in HIV-positive individuals receiving long-
term HAART treatment 13. Since rats were only moderately obese, it is likely that our 8-week 
experimental period is too short to induce profound hyperglycemia. The ipGTT unfortunately did not 
aid us in these investigations and the methods employed required further optimization. Such 
technical considerations are currently being assessed in our laboratory. This is unlike clinical 39 and in 
vitro 18 studies that previously reported the development of IR and the impairment of glucose uptake 
(via GLUT4) in response to PI treatment. However, these changes are very likely due to amount and 
duration of PI treatment. Additionally, the HOMA-IR and insulin levels confirmed our findings that our 
model is not insulin resistant nor in danger of developing a diabetic phenotype.   
 
Chronic PI therapy elevated LDL-cholesterol 
It is clear from the data that the elevation in LDL-cholesterol were not accompanied by similar 
changes in other lipid parameters and provide critical information as to how the PIs may elicit their 
metabolic response. The lipid profile was performed on serum samples, indicating that the increase in 
LDL-cholesterol very likely resulted from an increase in hepatic synthesis and release of cholesterol, 
even though total cholesterol levels remained unaltered. We also postulate that the increase in 
weight alongside lipid changes is indicative of the activation of key lipogenic and cholesterogenic 
genes within the liver and adipose tissues and may account for such an elevation. In addition, SREBPs 
play a central role by elevating gene transcription of key lipid synthesis genes such as hmg-cr 40,41 and 
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fas 42–46 and elevate the pool of cholesterol moieties. PIs have previously been shown to inhibit the 
UPS 47,48, a key modulator of SREBP metabolism, and thus it is a possibility that PIs may activate lipid 
synthesis and secretion via inhibition of the UPS and consequently exacerbate SREBP-induced gene 
transcription within the liver. Importantly, LDL-cholesterol may not necessarily translate into a pre-
atherogenic profile on its own, but the involvement of increased availability of FAs and cholesterol 
may alter homeostatic FAO rates and mitochondrial oxidative capacity. Excess substrate supply does 
not bode well for mitochondria and we hypothesize that it is mitochondria that bear the brunt of PI-
induced metabolic perturbations. This in turn may elicit downstream consequences e.g. oxidative 
stress, increased lipid peroxidation, insufficient mitochondrial energetics and ultimately cardiac 
inefficiency at multiple levels. 
 The fact that metabolic and phenotypic changes presented as early as 8 weeks requires 
attention. Many clinical models have reported lipid abnormalities with and without anthropometric 
changes in the context of PI treatment of more than one year 24–27,36,49. Though our animal model 
attempts to complement chronic clinical PI administration of 2-3 years, human and in vivo models do 
not always correlate fully. More importantly, LDL-cholesterol is a critical pre-atherogenic marker and 
a well-known risk factor for cardiovascular disease 1,8,50 and its singular elevation by chronic PI 
treatment further support our hypothesis: lipid changes occur at the gene level through key lipogenic 
mediators and contribute to the pre-atherogenic profile as well as MetS commonly seen in PI-treated 
HIV-positive patients. It is therefore imperative that the key mediators of such pathways be 
investigated and the underlying molecular mechanisms elucidated.  
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Conclusions 
 
Together this study shows that early changes induced by PI treatment resemble a pre-atherogenic 
state, a combination of risk factors that predispose to the future onset of IR, T2DM and CVD.   
Moreover, the higher serum LDL-cholesterol levels mirror the pre-atherogenic state that may 
eventually elicit the onset of various cardiac complications, e.g. acute MI. Altered metabolic pathways 
and mitochondrial regulation emerge as strong candidates that may play a role in this instance.      
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Chapter 3 
 
The effect of PIs on rat heart function 
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Introduction 
 
HIV infection is characterized by a compromised immune system and subsequent chronic, life-long 
inflammation and the development of AIDS. Cardiac abnormalities were noted as early as 1989 1,2 in 
the pre-HAART and included dilated cardiomyopathy, endo-, myo- and peri-carditis and pulmonary 
hypertension 1–4. Prevalence during this time period was between 28 - 73% 1,3,5. Importantly, HIV is 
able to directly infect cardiac tissue 6, though this may be attributed to the stage of HIV/AIDS but 
nonetheless compounds the future health outcomes and survival of an HIV-infected individual.  
In the era of HAART it is important to understand the relative contributions of ARVs and HIV 
infection to the onset of CVD and related manifestations, especially since HIV infection is a potential 
risk factor for CVD. In addition, HAART-associated cardiac complications are proposed to form distinct 
entities in terms of the development of CVD 7,8. Thus the focus has now shifted from the opportunistic 
infections due to HIV and AIDS, to HAART-associated metabolic and cardiovascular complications. This 
is particularly relevant in the context of extended lifespans.  
HIV PIs in particular, are strongly implicated in the onset of cardiovascular complications, with 
increased risk for MI and coronary syndromes. For example, in one of the largest clinical studies 
assessing the risk for myocardial infarction with HAART - the Data Collection for Adverse events of 
Anti-HIV drugs (DAD) Study Group recruited 23 468 HIV-positive patients on ART 9–11 - cumulative 
exposure to HAART saw a significant increase in the incidence of MI (26% relative change) with the 
most significant risk for MI due to PIs. Though the absolute risk for MI was low when adjusted for 
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confounding factors, cholesterol, lipid abnormalities and diabetes were highlighted as HAART and PIs 
exacerbate these traditional CVD risk factors. Similar results have been found in other large cohort 
studies  12,13 and PIs are significantly associated with the occurrence of MI 9,10,12–15. Further, longer-
term exposure to HAART regimens (including PIs) can increase mortality 11,16,17 and hospitalization for 
cardiovascular complications 18. Echocardiographic abnormalities have also been associated with the 
use of the PI, Ritonavir 19, i.e. 656 HIV-infected cohort baseline echocardiography revealed significant 
rates of left ventricular systolic dysfunction, diastolic dysfunction, pulmonary hypertension and left 
atrial enlargement. Though some studies do not support a link between PIs and atherosclerosis 15,20 
due to minimal differences between PIs and other ARVs in HAART, many other studies do report a 
clear connection with development of subclinical atherosclerotic lesions 21–24  and thrombotic 
environments 25,26. Thus it is not only the overt presentation of cardiac maladies, but also the 
subclinical progression that impacts on the development of future cardiac disease risk. 
In light of this there has been increased emphasis on delineating the underlying mechanisms 
driving HIV/HAART-mediated cardiovascular complications and thus oxidative stress is known to be an 
important factor within the context of cardiovascular pathology. For example, it is especially relevant 
during chronically activated immune activation with HIV infection. Moreover, under such conditions, 
ECC can become disrupted and have negative consequences in terms of cardiac myofiber physiology. 
For example, the RyR 27–30, SERCA 31–36 and NCX 37–39 channels are sensitive to oxidation that may 
result in altered functional effects, i.e. pathologically opened or closed. Calcium overload may then 
arise and this can lead to disastrous downstream effects, especially at the mitochondrial and 
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contractile level; namely, a further exacerbation of ionic imbalance and toxicity, and perturbed redox 
status of the myocardium. Here, excess ROS within the myocardium can inhibit calcium-ATP-
hydrolysis coupling 31 since cardiac calcium homeostasis is highly sensitive to oxidative stress 40–42. 
High intracellular calcium levels can also induce hyperactivation of electrical system leading to 
impaired cardiac contractile function. However, despite such progress not much is known regarding 
mechanisms driving contractile dysfunction with HIV/HAART. Moreover, it is often difficult to tease 
out the relative contributions of HIV and HAART, respectively, in this instance. 
      In light of this, we investigated ex vivo and in vivo heart function in a healthy rodent chronically 
treated with PIs, since as far as we are aware, this has not been performed previously. The aims were 
to characterize heart function of rats treated with HIV PIs for 8 weeks and to further elucidate the 
early molecular mechanisms underlying these processes. Here we made use of the Langendorff 
retrograde heart perfusion model (ex vivo) to study heart function for 60 min with an addition 
ischemia-reperfusion period. Further, the effect of a HF diet (refer to Chapter 2) co-administered with 
PIs was assessed to determine if any cumulative effect of treatment would occur. In addition, an in 
vivo model of ECG monitoring was also utilized. These data should provide significant insight 
regarding how these detrimental side effects can occur with PI usage.  
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Materials & Methods 
 
Animal model 
The use of animals and procedures were reviewed and approved by the Animal Research 
Ethics Committee of the Faculty of Natural Sciences of Stellenbosch University as discussed in Chapter 
2 (application numbers 2006B02006, 11NF_REY01, SU_ACUM11_00006, 012/005 AEC 012/005 and 
related amendments).  
Drug administration 
 Lopinavir/Ritonavir (KaletraTM, Abbott Laboratories, Abbot Park IL) was crushed and dissolved 
in a 1% ethanol (vehicle) solution at human steady-state plasma concentration (7.1 ± 2.9 µg/mL), 
sterile filtered and injected into a mini-osmotic pump (Alzet, Cupertino CA) as previously described 
(Chapter 2). 
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A. Ex vivo Working Heart Perfusions 
 
Working heart perfusion method 
As previously described (Chapter 2) rats were administered PIs and a HF diet for 8 weeks, with 
8 animals per experimental group. Assessment of heart function and recovery after an ischemic attack 
was investigated using the working heart perfusion technique 43. Rats were euthanized with a single 
injection of pentobarbitone sodium (100 mg/kg) and hearts rapidly excised and placed in ice-cold 
Krebs-Henseleit buffer (in mmol/L: NaCl 118.0, KCl 4.7, MgSO47H2O 1.2, CaCl2 1.25, NaHCO3 25.0, 
KH2PO4 1.2, and glucose 11). Hearts were cannulated to the perfusion apparatus within 50 sec and 
retrograde perfusion initiated with Krebs-Henseleit buffer at 37.0 ± 0.5oC with a pressure of 80 cm 
H2O, while the pulmonary vein was cannulated as well.  Perfusion in the retrograde mode stabilized 
the heart for 20 min. The perfusion rig was set up as illustrated in Fig. 1. To evaluate baseline 
function, hearts were then perfused in the working mode with 15 cm H2O preload and 80 cm H2O 
afterload pressure for 50 min with a palmitate-containing Krebs-Henseleit buffer (Fig. 2). Palmitate 
(0.4 mM) was conjugated to bovine serum albumin (BSA) (BSA Fraction V, Roche Diagnostics, IN USA) 
and prepared as described previously 43. The BSA contributed 0.3 mM FA towards the FA 
concentration, i.e. 0.7 mM total.   
 Functional recovery was assessed by inducing global ischemia for 10 min in the working mode 
after stabilization for 35 min (Fig. 2), with the heart submerged in buffer at 37.0 ± 0.5oC to ensure 
correct simulation of the in vivo environment. Thereafter the buffer was drained and retrograde flow 
to the heart was once again initiated for 15 min with original Krebs buffer, followed by the working 
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mode for 20 min (with palmitate-containing Krebs buffer). Measurements of heart function and 
recovery (coronary and aortic flow, heart rate, aortic diastolic and systolic pressure, mean arterial 
pressure [MAP] and rate-pressure-product [RPP] [RPP = left ventricular developed pressure [LVDP] x 
heart rate]) were recorded throughout the perfusions and analyzed by employing ADInstumentsTM 
LabChart Pro v.7 software (ADInstruments, NSW, Australia). At the end of the protocol hearts were 
quickly removed from the cannula and weighed and immediately snap frozen in liquid nitrogen and 
stored at -80oC. All perfusion buffers were maintained at a constant temperature of 37.0 ± 0.5oC via a 
water-jacketed apparatus. 
Statistical analyses. 
Two-way ANOVA was utilized for all experiments with a Bonferroni post-hoc test to compare 
variation between all the groups. Statistical significance was considered when p<0.05.  
Only the mean + SEM is graphically represented for easy visualization, but the data have been 
analyzed as mean ± SEM. 
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Figure 1. Working heart perfusion rig set-up. The heart is cannulated via the pulmonary vein (PV) and 
Krebs-Henseleit buffer flows through the left atrium (LA) into the left ventricle (LV) to create preload 
conditions. Perfusate is then pumped back through the right atrium (RA) and into the compliance 
chamber, where the overflow (aortic output) are measured via a flow probe. This mimics the in vivo 
pressure conditions and creates an aortic pressure that can be measured via a flow probe to indicate 
aortic flow rate amongst other measures of working heart function. Arrows indicate direction of flow 
of perfusate during working mode. AO – aortic outlet, RV – right ventricle. 
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Figure 2. Baseline function and ischemia-reperfusion protocol for working heart perfusions. Hearts 
were perfused according to the above protocol with specified durations of stabilization, working heart 
perfusion, ischemia as well as reperfusion. 
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Results 
 
To assess the effects of PI therapy as well as dietary intervention, heart functional analyses were 
performed using the working heart perfusion method. With the cannulation of the pulmonary vein, ex 
vivo pre- and after-load conditions were mimicked. During the stabilization phase, baseline MAP was 
not significantly different between any of the groups (p>0.05) (Fig. 3A), however, upon induction of 
the working mode it became apparent that the experimental set up might not be correct. MAP was 
non-existent for the vehicle group and declined significantly for all other treatment groups (PI – 31.7 ± 
0.0 mmHg, HF – 27.9 ± 11.8 mmHg) to below the accepted cut-off for working heart perfusions. Heart 
rate during the stabilization period for both PI and HF groups were slightly below the range for Wistar 
rats (169-204 beats/minute) and did not alter significantly during the working phase (Fig. 3B). 
Coronary flow, however, proved the failed experiment further (Fig. 3C) as working heart perfusion 
flow rates were between 3.0-3.7 mL/min, well below the range expected during this type of 
perfusion. These alterations, or lack thereof where found in all treatment groups, and some groups 
refused to perform and had zero values. Further assessments such as RPP confirmed this (Fig. 4). In a 
separate but similar experiment excluding the sham and HF diet group (due to previous data), 
ischemia-reperfusion showed similar results. MAP, heart rate, coronary flow and RPP (Fig. 5) all 
significantly decreased below the accepted range and indicated that the hearts were not producing 
enough pressure and not functioning correctly. 
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Figure 3. Baseline working heart function in response to PI and high fat treatment (n=8). Perfusion 
protocol indicated on graph. A) Mean arterial pressure; B) Heart rate; and C) Coronary flow separated 
per treatment group (PI treatment ± HF diet). Data presented as mean ± SEM. HF – high fat, PI – 
protease inhibitor. 
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Figure 4. Rate-pressure product at baseline in response to PI treatment ± high fat diet (n=8). 
Perfusion protocol indicated on graph. A) RPP for PI treatment; and B) RPP for HF dietary intervention. 
Data presented as mean ± SEM. HF – high fat, PI – protease inhibitor, RPP – rate-pressure product.  
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Figure 5. Heart function in response to ischemia-reperfusion with PI treatment (n=8). Perfusion 
protocol indicated on graph. A) Mean arterial pressure; B) Heart rate; C) Coronary flow; and D) RPP. 
Data presented as mean ± SEM. RPP – rate-pressure product, PI – protease inhibitor. 
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Discussion 
 
Due to experimental complications, it was apparent that the working heart perfusion technique was 
not suited to assessing heart function with PI treatment and a HF diet. This was noted in all 
parameters during baseline and ischemia-reperfusion experiments. Although the stabilization phase 
appeared normal, the hearts failed to perform when put in the working mode.  
 Importantly, this technique was first discovered as a means to measure oxygen consumption 
and energy metabolism within an ex vivo setting. In 1967 Neely and colleagues 44 proposed a novel 
technique to investigate pressure development on oxygen consumption in an isolated rat heart, and 
this was further modified and improved upon by Taegtmeyer et al. (1980) 45.  Many other studies 
have since made use of this technique with success 46–48.  
The technique is, however, not fool-proof and comes with a myriad of parameters that can 
and must be controlled correctly to ensure a working perfusion. Apart from mimicking in vivo 
pressure conditions by setting the preload on the heart to 11-15 cm H2O and afterload at 80-100 cm 
H2O, oxygenation of the buffer, flow rate, substrates present in the perfusate buffer and set-up of the 
compliance chamber all play a very big role in the success of the experiment 43. In this experiment we 
made use of the conventional 15 cm preload and 80 cm afterload with 1 cm3 airspace within the 
compliance chamber. This set of parameters was chosen with the advice of colleagues experienced in 
the technique. Further, Lopaschuk et al. (1997) 43 mention that the volume of air within the 
compliance chamber is traditionally suited to rats weighing 250-300 g. However, others 49 have 
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successfully employed it in rats weighing >500 g, which is more within the current study’s body weight 
range and would therefore have been expected to be successful.  
The use of FAs within the perfusate buffer was also carefully considered as the heart requires 
both carbohydrates and fats as energy sources, though relies on FAs in vivo for the majority of its 
energy requirements and carbohydrates during fetal development 50. Further studies have made use 
of additional substrates such as oleate, insulin and pharmacological substances to manipulate 
experimental conditions depending on the hypothesis 46–48. One could argue that our perfusate buffer 
did not contain insulin to mediate glucose uptake, but many research groups have/have not always 
included additional substrates and since 1965 it has remained controversial as to the provision and 
type of substrates (articles and reviews 51–60).  
The fact that the coronary flow and subsequently aortic output was zero indicates a more 
fundamental problem with the system’s set-up, as aortic output is expected to be between 30-40 
mL/min. It could very well be that the hearts were incorrectly cannulated at the pulmonary vein, 
leading towards incorrect pressure development and contractile dysfunction. This remains a 
possibility even though the investigator was thoroughly trained in performing the technique and had 
great success during practice runs.  
Since our data yielded very promising results in terms of phenotypic characterization and 
insights into the molecular mechanisms of PIs (Chapter 2), an alternative but similar method was 
chosen: Langendorff retrograde heart perfusion. The Langendorff technique is relatively easy to 
master, requires minimal financial investment, and can render high-quality data within a relatively 
short period. We therefore pursued this type of analysis since no-one (as far as we are aware) has 
previously investigated ex vivo heart function in response to HIV PIs. 
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Conclusion 
 
Although the experiment with the working heart perfusion technique was unsuccessful, it provided 
valuable practical experience for the investigator. Since our animal model has thus far provided 
valuable insights regarding the phenotypic and molecular changes induced by PI therapy, we next 
decided to use the Langendorff retrograde perfusion method to evaluate heart function parameters.  
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B. Ex vivo Langendorff Perfusions 
 
Ex vivo Langendorff heart perfusion method 
Due to financial constraints, rats did not receive any special dietary interventions for this set of 
experiments, and were thus placed on the traditional in-house animal diet. A pilot study assessing 
functional differences between the commercially obtained control diet and the traditional in-house 
animal house diet revealed no significant differences, indicating that it was appropriate to continue 
with the in-house diet. We analyzed 3 treatment groups: sham, vehicle- and PI-treated. Identical 
protocols as indicated in the beginning of this chapter were used in terms of housing and intervention 
duration. 
Heart Function. At the end of the 8-week treatment period rats were anesthetized and hearts 
removed as previously described for ex vivo working heart perfusions with similar Krebs-Henseleit 
perfusate buffer (no FAs) and cannulated on a Langendorff perfusion rig (Fig. 6). We could not include 
FAs for the experiment due to cost of the BSA required for conjugation. To assess baseline function, 
hearts were retrogradely perfused 48  – 60 min perfusion period – via a water-filled latex balloon 
inserted into the left ventricle and diastolic pressure set between 5-15 mmHg. Hearts that did not 
produce a systolic pressure ≥ 70 mmHg and/or did not produce a coronary flow rate of 8-16 mL/min 
were excluded from analyses.   
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Figure 6. Retrograde Langendorff perfusion rig set-up. The heart is cannulated via the aortic branch 
(at AO) and through the flow of perfusate buffer at the osteoclasts situated just above the aortic 
valves, spontaneous firing of the S-A node is stimulated and contraction of the myocardium ensues. 
Through insertion of a latex balloon via the pulmonary vein (PV) into the left ventricle (LV), ventricular 
pressure and related measurements can be made and recorded with appropriate software on a PC. 
The coronary flow rate is measure via the amount of overflow perfusate from the heart into the heart 
chamber and measured via a flow probe. AO– aortic outlet, PC – personal computer, RA – right 
atrium, RV – right ventricle. 
Stellenbosch University  http://scholar.sun.ac.za
129 
 
For the ischemia-reperfusion experiments, the 60 min stabilization period was followed by 30 
min of global ischemia and 60 min of reperfusion.  The experimental protocol is depicted in Fig. 7. 
Contractile parameters were assessed via pressure transducer (Stratham MLT 0380/D, ADInstruments 
Inc., NSW, Australia) included heart rate, LVDP, and RPP.   Ventricular tissues were collected at the 
end of each experiment, freeze-clamped and stored at -80°C for further molecular and biochemical 
analyses.   
Infarct Size. In a parallel but separate experiment (since ventricular tissue had already been 
collected), infarct sizes in response to regional ischemia were determined as previously described 48. 
Briefly, after 60 min stabilization a period of 30 min of regional ischemia (cannulation of left anterior 
descending coronary artery via silk suture) was followed by 2 hrs reperfusion period (Fig. 7).  The 
extended reperfusion period ensured flushing out of components that might interfere with the 
staining procedure. Thereafter, the suture was re-tightened and 2.5% Evans Blue dye (in Krebs-
Henseleit buffer) perfused through the hearts. Hearts were subsequently removed from the 
Langendorff apparatus, blotted dry, suspended within 50 mL plastic tubes (using suture) and frozen at 
-20°C for 3 days. Frozen hearts were sliced into 2 mm transverse sections and incubated with 1% 
2,3,5-triphenyl tetrazolium chloride (TTC) in phosphate-buffered saline (PBS) for 20 min at 37°C to 
identify non-infarcted (stained) from infarcted (non-stained) tissues. Slices were then fixed in 10% 
formalin for 24 hrs at room temperature before being placed between glass plates for scanning (both 
sides). The infarct area (IA) and the area at risk (AAR) size were calculated using Image J software 
(v1.46p, National Institutes of Health, USA). Values of tissue slices were added together in order to 
obtain the total IA and AAR for each heart analyzed. Infarct sizes in the sham group exceeding 60% 
were excluded due to the fact that this would represent a technical error (on the part of the 
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researcher) and should not be present in a control environment. We expressed the infarct size as the 
ratio of IA versus the AAR (% IA/AAR) for each heart analyzed (n=4-6). 
 
Figure 7. Langendorff retrograde perfusion protocol. Perfusion and ischemia durations are indicated 
for both heart functional assessment and infarct size analyses. 
 
Statistical analyses 
 Two-way ANOVA was performed for all 3 groups for heart function, with a Bonferroni post-hoc 
test comparing all experimental groups to each other. One-way ANOVA was used to assess infarct 
size. Significance is indicted on graphs, and only the + SEM bar is represented for ease of visualization 
where necessary, though data was calculated as mean ± SEM. Significance is considered when p<0.05. 
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Results 
 
Baseline heart function 
Since PIs can negatively impact on heart function in HIV-positive patients, the aim of this study was to 
assess heart function in rats treated with PIs for 8 weeks. The heart weight to body weight ratio was 
calculated (as a marker of hypertrophy) and here experimental groups presented with similar ratios 
(p>0.05) (Fig. 8). This therefore indicates a lack of hypertrophic response at this early time point.   
 
Figure 8. Heart-to-body weight ratio in response to 8 weeks PI treatment (n=8). After 8 weeks PI 
therapy heart weight was compared to body weight. Data presented as mean ± SEM. PI – protease 
inhibitor. 
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We next evaluated baseline heart function parameters. Both heart rate and coronary flow rate 
remained unaltered during the 60 min perfusion period in all experimental groups (p>0.05) (Fig. 9). 
 
 
 
Figure 9. Baseline heart functional parameters for 8 weeks PI treatment (n=8). During ex vivo 
Langendorff perfusion heart rate and coronary flow of rats treated with PIs for a total of 8 weeks was 
measured. Data presented as mean ± SEM. PI – protease inhibitor. 
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Ex vivo perfusion data further revealed that PI treatment was detrimental to heart function 
(Fig. 10). PIs decreased LVDP to 35.50 ± 1.55 mmHg vs. 60.88 ± 2.4 mmHg (sham) (p<0.01) and vs. 
53.14 ± 6.61 mmHg (vehicle) (p<0.001).  Likewise, RPP was also attenuated in PI-treated hearts vs. 
matched controls. Further, maximal and minimal contractile force (±dP/dt) were significantly 
diminished at baseline throughout the baseline period (+dP/dt – PI 633.1 ± 57.7 vs. sham 1411.0 ± 
126.9 mmHg/sec, p<0.001; vs. vehicle  1068.8 ± 70.9 mmHg/sec, p<0.05; - dP/dt – PI -338.4 ± 31.0 vs. 
sham -966.8 ± 71.9 mmHg/sec, p<0.001; vs. vehicle -782.1 ± 118.2 mmHg/sec, p<0.01). 
 
 
Figure 10. Additional baseline heart functional parameters in response to 8 weeks PI therapy (n=8). 
Baseline parameters were assessed for 60 min include LVDP, RPP, maximal and minimal contractile 
force. Data presented as mean ± SEM. **p<0.01, ***p<0.001 vs. sham; #p<0.05, ##p<0.01, 
###p<0.001 vs. vehicle. LVDP – left ventricular developed pressure, RPP – rate-pressure product, PI – 
protease inhibitor.  
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Response to ischemia-reperfusion 
We next evaluated how PI-treated hearts would respond to ischemia-reperfusion (Fig. 11). 
Coronary flow remained unchanged (p>0.05) during ischemia-reperfusion, however, heart rate was 
significantly diminished in PI-treated animals after 60 min of reperfusion, i.e. decrease in heart rate to 
22.0 ± 22 beats/min compared to 203.9 ± 26 beats/min, p<0.001 (sham) and 180.0 ± 35 beats/min, 
p<0.01 (vehicle).    
 
 
Figure 11. Contractile parameters after ischemia reperfusion in response to 8 weeks PI treatment 
(n=8). **p<0.01, ***p<0.001 vs. sham;  ##p<0.01 vs. vehicle. PI – protease inhibitor. 
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Ischemia-reperfusion in the context of chronic PI treatment elicited similar detrimental effects 
on many other parameters. Here LVDP decreased in the PI-treated group in response to global 
ischemia, i.e. PI to 3.0 ± 2.36 mmHg vs. sham 35.38 ± 7.03 mmHg (p<0.001) and vs. vehicle 27.43 ± 
5.07 mmHg (p<0.05) (Fig. 12).  A similar pattern was found for RPP. Maximal and minimal contractile 
force was significantly decreased with PI treatment compared to sham animals (p<0.05) at many 
points during reperfusion, but no similar significance was obtained when compared to vehicle-treated 
rats (Fig. 12). 
 
 
 
Figure 12. Additional contractile parameters during ischemia-reperfusion (n=8). Contractile 
parameters after ischemia-reperfusion in response to 8 weeks of PI therapy. *p<0.05, **p<0.01, 
***p<0.001 vs. sham; #p<0.05, ##p<0.01, ###p<0.001 vs. vehicle. LVDP – left ventricular developed 
pressure, PI – protease inhibitor, RPP – rate –pressure product. 
Stellenbosch University  http://scholar.sun.ac.za
136 
 
Interestingly, the percentage of LVDP recovery with global ischemia was not significantly 
different for PI treated groups vs. matched controls (p>0.05) (Fig. 13). Nonetheless, the survival rate 
dramatically decline after 30 min global ischemia where 50% of hearts treated with PIs did not 
perform adequately. Sham and vehicle-treated rats experienced up to a 20% decline in survival rate 
(Fig. 13). 
 
 
Figure 13. Recovery of LVDP and survival rate after ischemia-reperfusion with PI treatment (n=8). 
LVDP after ischemia-reperfusion was compared to baseline LVDP and expressed as a percentage, and 
number of hearts surviving the ischemia-reperfusion protocol expressed as percentage survival. LVDP 
– left ventricular developed pressure, PI – protease inhibitor. 
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Infarct size assessment 
In separate experiments, PIs increased infarct size to 79.2 ± 40.7% vs. 46.3 ± 5.7% (sham) (p<0.01) and 
vs. 39.4 ± 8.4% (vehicle) (p<0.01) (Fig. 14). These data indicate that PIs are detrimental to heart 
function at many levels. 
 
 
 
 
Figure 14. Infarct size in response to 8 weeks PI therapy (n=8). Infarct size was measured and 
expressed as a percentage of the area at risk in rats treated with PIs. Data presented as mean ± SEM.  
**p<0.01 vs. sham, ##p<0.01 vs. vehicle. AAR – area at risk, PI – protease inhibitor.  
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Discussion 
 
Our baseline heart functional data show significant differences with PI treatment. Relaxation of the 
cardiac musculature was impaired at baseline and confirmed with additional parameters. Due to the 
fact that 50% of the PI group experienced failure with ischemia-reperfusion, this illuminates the 
possibility that electrical signaling within the heart and calcium homeostasis may be impaired.  
 Electrical conductance and calcium physiology must be taken in to consideration as our 
functional data point towards impairment of signal propagation and cross-bridge formation 
physiology. Alterations to calcium homeostasis can have a significant impact on heart function, as 
calcium enables ECC to take place 61. In addition, maintenance of the calcium gradient by calcium 
pumps (e.g. SERCA) can influence calcium supply and removal from the myofiber. The rate of calcium 
removal determines the resting tension and resting calcium concentration within the myofiber 62, 
which in turn has a direct effect on the contractile force generated and also calcium available during 
the next contractile cycle. Importantly, heart rate was not significantly altered within our model with 
PI treatment and points toward a molecular and electrical pathology. Here, the depolarizing wave is 
still propagated at regular intervals but the translation into physical myofiber coupling and molecular 
interactions are impaired. Thus maximal contractile and relaxation force cannot be reached due to an 
imbalanced ionic and electrical homeostasis at various levels. Calcium contractile proteins such as 
calmodulin, calcineurin and CaMKII as well as SERCA and its regulator PLB need to be further 
investigated to elucidate this pathological mechanism.  
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 These data therefore suggest that PI therapy decreases the heart’s output and triggers a 
response within heart cells and mitochondria that could lead to disruption of electrical signaling. This 
may also be due to increased oxidative and energetic stress within cardiac mitochondria. We propose 
that PIs increase ROS production leading to mitochondrial damage and that the decline in heart 
function is mediated by an imbalance in calcium homeostasis and SR-related ion channels. Not only is 
calcium important during ECC, it is essential in maintaining calcium and ionic homeostasis within 
mitochondria. However, these concepts require further investigation. 
It is important to note that these changes are present at a fairly early stage. Here we speculate 
that damaged mitochondria may trigger intracellular signaling cascades and gene transcription 
pathways to increase mitochondrial ATP production and antioxidant defense systems, for example 
SOD and catalase. Increased mitochondrial respiration would generate higher ATP levels leading to a 
greater amount of ROS produced by mitochondrial respiration complexes I and III, but also oxygen 
radicals such as O2
• - and H2O2. These intriguing possibilities are currently being pursued in our 
laboratory. 
Although we found significant differences in functional data at baseline, the PI-treatment 
group did not respond differently to the other groups in response to ischemia-reperfusion. Though 
heart rate declined significantly after 1 hr of reperfusion, LVDP recovery of the PI-treated hearts was 
not different to that of the controls. These data therefore indicate that although no significant 
phenotype is displayed after ischemia-reperfusion - PI treatment elicits molecular changes within the 
heart cell at baseline. Thus, even before an ischemic attack the heart is at a disadvantage but does not 
translate similarly thereafter. We propose that these changes are largely centred on PI-induced ionic 
imbalance, ROS generation and its possibly mitochondrial effects. This is in agreement with previous 
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studies that showed that Lopinavir treatment caused detrimental effects (via oxidative stress) on 
cardiac mitochondria 63. Moreover, PIs are able to decrease the mitochondrial membrane potential 
causing a disruption in the electrochemical proton gradient essential for the production of ATP 
(reviewed in 64). The activities of ETC complexes I and III can also be impaired by ROS, i.e. indirectly via 
activation of proteins and/or by impairment of electron flow through the ETC 65. Thus a vicious cycle is 
established since more electrons leak into the mitochondrial matrix and the inter-mitochondrial 
membrane space, generating even more damaging ROS 66. 
 The consequences of PI administration on mitochondria and the myocardium are immense: 
mitochondrial toxicity from ROS; impaired respiratory capacity and energetics, impaired contractile 
functioning and disrupted metabolism, and are further exacerbated during ischemia-reperfusion.   
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Conclusion 
 
These data reveal that PIs are detrimental to contractile function of the rat heart and we predict it 
creates a pathological environment of ionic imbalance and greater oxidative environment. Calcium 
signaling, ionic pumps, ROS and mitochondrial metabolism have been implicated as potential targets. 
These targets shall be further investigated to fully elucidate the mechanisms behind PI-associated 
heart dysfunction. In vivo heart function assessments in the form of an ECG will take place to 
corroborate our ex vivo findings and to fully investigate electrical conductance. Ultimately, these 
findings indicate that – when projected to the clinical setting – the patients’ risk for cardiovascular 
and metabolic-related disease is increased in the long term with PI-containing HAART.  
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C. In vivo heart function assessments 
 
In vivo heart function method 
 This functional assessment took place in collaboration with Dr. Roisin Kelly-Laubscher at the 
University of Cape Town, and complied with the necessary ethical procedures and housing 
requirements. Rats were handled as described previously (ex vivo Langendorff perfusions). At the end 
of the 8 week treatment period with PIs (no dietary interventions) rats were anesthetized with 
sodium pentobarbital (60 mg/kg i.p.), intubated, and thereafter ventilated with room air (2.5 
mL/stroke) at a rate of 75 strokes/min via a rodent ventilator (Model 681, Harvard Apparatus, USA). 
Body temperature was monitored by a rectal temperature probe and a constant temperature was 
maintained throughout the surgical procedure by placing rats on a custom-made heating block. The 
depth of anesthesia was checked by assessing the pedal withdrawal reflex and by monitoring heart 
rate. Maintenance doses of anesthetic (6 mg/kg i.p.) were administered as required.  
Lead II ECG was recorded via an Animal Bio Amplifier (ML136, ADInstruments, NSW, Australia). 
Carotid arterial blood pressure was recorded via a custom-made cannula attached to a pressure 
transducer (MLT0670, ADInstruments, NSW, Australia). Since formation of clots around intra-arterial 
cannulae poses a potential risk for arterial thrombosis, heparin (1000 IU/ kg i.p.) was injected 
concurrently with anesthetic 67,68. A left thoracotomy was performed through the 4th intercostal space 
and the left lung collapsed using a damp swab. The left anterior descending coronary artery was 
thereafter ligated as previously described 69. A 6–0 silk suture was placed around the left anterior 
descending coronary artery and its ends passed through a plastic tube. For induction of regional 
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ischemia the ends of the suture were used as a snare to occlude the artery by applying it gently onto 
the ventricular surface for 30 min. The efficacy of ischemia was confirmed by regional cyanosis and 
ECG changes. We employed S-T elevation (ECG) to confirm coronary artery ligation. The snare was 
released during reperfusion. Rat hearts were subjected to 30 min regional ischemia followed by 2 hrs 
of reperfusion. Upon termination of the experiment, rats were exsanguinated and hearts removed for 
in vivo infarct size assessment as previously described (ex vivo Langendorff perfusions). Equipment 
and procedure are depicted in Fig. 15 and Fig. 16. 
 
Figure 15. The materials used for recording the rat blood pressure in vivo. A) Bulldog clamp; B) 
Polyethylene tube [15-20 cm length] with a 26 G x ½” needle for carotid artery cannulation;  and C) 
Disposable clip-on blood pressure transducer 70. 
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Figure 16. Cannulation of the carotid artery. A) Right side of the carotid artery is separated from the 
vagus nerve; B) and C) Cephalic end of the blood vessel is tied to avoid the bifurcation of blood 
pressure; D) Cardiac end of the blood vessel is clamped with a bulldog clamp for cannulation; E) Small 
platform is placed in the cannulation site; F - I) Carotid artery is cannulated and tied; J - K) The support 
platform and bulldog clamp are removed and ensure there is no leakage in the cannulation; and L) 
The carotid cannula is connected to the pressure transducer 70. 
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Results 
 
The ex vivo heart function data indicated that PIs have a severe effect on heart function with a failure 
rate of 50% after ischemia-reperfusion, therefore the aim was to translate and compare these 
findings within an in vivo setting. Here a similar protocol was utilized; namely, 1) baseline heart 
function assessment and 2) regional ischemia followed by reperfusion and post-ischemic recovery 
assessment.  
Each experimental group started out with 10 designated rats and subsequently anesthetized 
and intubated. However, the researchers experienced much difficulty with the handling of the rats 
throughout the protocol, with respiratory distress and anesthetic overload being potential (but not 
proven) factors. This led to a very small number of successful baseline recordings, far below what is 
statistically scientifically adequate for comparison.  For both PI- and vehicle-treated groups, we could 
only complete 5 valid and useful ECG readings, while sham and control groups had a failure rate of 60 
and 80%, respectively (Table I). Comparison of ECG and pressure recordings reveal that rats that were 
unsuccessful had a markedly abnormal ECG – no clear electrical patterns with excess noise, while 
successful recording show the correct ECG wave pattern – namely a QRST wave (Fig. 17). 
Unfortunately, halfway during the experimental procedure the manometer refused to work, and 
although aortic blood pressure was then measured using a pressure transducer its accuracy was not 
trusted and therefore it was decided not to interpret the pressure recordings. These problems were 
present within all experimental groups during baseline as well as ischemia-reperfusion. 
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Table I. Number of animals used for in vivo heart functional assessment and success with 
experiments. 
 Control Sham Vehicle PI 
Starting number 10 10 10 10 
Succeful at Baseline 2 4 5 5 
Failure rate (%) 80 60 50 50 
   PI – protease inhibitor 
 
Figure 17. ECG recordings at baseline. ECG readings (in red, mV) as well as aortic blood pressure (in 
blue, mmHg) where recorded. Panel A and B indicate correct ECG recordings while panel C and D 
show incorrect ECG recordings.  Panel D also indicates at the blue line that the manometer refused to 
work and could not generate pressure recordings. ECG – electro-cardiogram. 
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ECG parameters were further assessed in rats that survived the intubation as well as the 
ischemia-reperfusion. Significant differences were found between the experimental groups at 
baseline (Fig. 18) where P-wave amplitude was significantly elevated in comparison only to sham 
(0.109 ± 0.007 mV vs. 0.055 ± 0.02 mV, p<0.05), and ST-wave height significantly decreased (-0.014 ± 
0.03 vs. sham -0.120 mV ± 0.02, p<0.05; vs. vehicle -0.14 mV ± 0.03, p<0.05). Parameters for post-
ischemic function remained unaltered (p>0.05) (Fig. 19). However, due to the low number analyzed 
per group, especially the control groups, no definite conclusion can be drawn from these experiments 
as all experimental groups require at least n=4-5 to be statistically relevant.  
 
 
Figure 18. Baseline ECG parameters in response to PI treatment (n=2-5). A) Heart rate; B) QRS 
interval; C) P wave amplitude; and D) ST height. Data represented as mean ± SEM. *p<0.05 vs. sham, 
#p<0.05 vs. vehicle. ECG – electro-cardiogram, PI – protease inhibitor. 
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Figure 19. Post-ischemic ECG parameters in response to PI therapy (n=2-5). Hearts were subjected to 
30 min regional ischemia and thereafter 2 hr of reperfusion in vivo. A) Heart rate; B) QRS interval; C) P 
wave amplitude; and D) ST height. Data represented as mean ± SEM. ECG – electro-cardiogram, PI – 
protease inhibitor. 
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Discussion 
 
The aim of the in vivo heart function determination was not only to corroborate the ex vivo findings 
but to generate novel data to improve our understanding of the detrimental effects of PIs on heart 
function. An ECG can shed light in to the inner workings and ionic physiology behind a contraction and 
would thus aid our interpretation of ionic and calcium homeostasis.  
 The advantage of an in vivo rat model is that ECG analysis is standardized, relatively cheap and 
straightforward to perform, easy to manipulate with drugs and has less confounding pre-existing 
diseases 71. The ECG was pioneered in the 19th century 72 and Farraj et al. (2011) 73 describe it as 
“…the spatio-temporal changes in the distribution of the extracellular voltage field present at the body 
surface and is directly related to the local voltage field generated by its source, the heart”. Although 
the ECG is not a direct functional measurement, it can detect rhythm disturbances and abnormal 
conductance as well as ischemic injury 74. The ECG is routinely used in health care but rats and 
humans differ in terms of heart rate and ECG pattern. The heart rate of a rat is typically between 300-
500 beats/min 75–77 while that of a human is around 60-100 beats/min. This can also be attributed to 
the fact that the human action potential duration is 5 times longer than that of a rat 71. Therefore, the 
ECG can impart important information about electrical conductance in the rat heart.  
 Due to unforeseen circumstances this experiment did not go as planned and with the aid of 
our collaborator, Dr. Kelly-Laubscher, her expertise was sought as to the reason. It was noted that 
many of the animals had respiratory difficulty from the time of intubation and during the procedure, 
even though intubation was successful and the correct volume of air circulated at the correct tempo. 
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The animal housing facility conducted routine tests and did not indicate danger for respiratory 
infections. At times it seemed that the larger rats would accumulate anesthetic within their fat pads, 
even though the anesthetic was correctly injected (i.p.). It has been noted before that PI-treated 
animals exhibit greater weight gain than their control counterparts and this was visually confirmed by 
the presence of excess abdominal adipose tissue while dissecting the animals in a separate study. Dr. 
Kelly-Laubscher also indicated that the rats might have been too old for this type of procedure, as her 
experience points towards younger (2 months or less) rats being successful with this technique. 
However, it is difficult to pinpoint the exact nature or causes why the ECG experiments failed. Due to 
the low number of successful ECG readings generated, we decided not to conclude anything from 
these data and instead focus on our ex vivo findings. 
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Conclusion 
 
Due to unforeseen circumstances, data generated from in vivo heart functional assessments could not 
be fully utilized to help elucidate the molecular and ionic pathology of PI-induced heart dysfunction. 
No definitive conclusion is therefore derived from these experiments. Tissue samples and functional 
data from ex vivo assessments were therefore utilized and studied in subsequent experiments. 
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Chapter 4 
 
Investigation of molecular mechanisms underlying 
cardio-metabolic dysfunction with HIV PI therapy. 
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Introduction 
 
PIs form an integral part of HAART and side-effects include development of dyslipidemia, i.e. greater 
production of plasma triglycerides and lipids together with an adverse cholesterol profile 6–8. Together 
such derangements elicit inflammation, stress the myocardium 9, and may potentially predict the 
onset of IR 10,11 and cardiac dysfunction 10. PIs are also linked to increased risk for myocardial 
infarction 12 and cardiovascular abnormalities 13,14, with many changes resembling coronary artery 
disease 15.  Therefore, an emerging focus is to identify key metabolic and transcriptional pathways 
that mediate PI-induced cardio-metabolic pathophysiology. For example, our data show that rats 
exposed to 8 weeks of PI treatment displayed cardiac dysfunction (Chapter 3) 16.  Moreover, PI-
treated HIV-infected individuals exhibit elevated ROS production 17–19 that may trigger the activation 
of detrimental signaling and cell death pathways 20.  
HIV-PIs may also exert unfavorable effects at the gene transcriptional level, e.g. activating 
SREBP21, a key lipid transcriptional modulator expressed in major metabolic tissues 22.  Upon 
activation, SREBP binds to SRE-containing promoter sequences in lipogenic and cholesterogenic genes 
(e.g. hmgcr) that ultimately results in the production of cholesterol (high-density lipoprotein [HDL] 
and LDL) and sterol components 23.   The UPS – responsible for removal of misfolded or damaged 
proteins - is also implicated in the onset of such metabolic side effects. For example, the PI Ritonavir 
attenuates chymotrypsin- and trypsin-like activities of the 20S UPS subunit in hepatocytes 24.  As a 
result, degradation of ApoB (major determinant of plasma lipid levels) was diminished thus providing 
a potential mechanism for PI-induced hyperlipidemia 25. Furthermore, SREBPs are ubiquitinated and 
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degraded by the UPS 26,27 raising the possibility that an inhibition of this system may also contribute to 
development of dyslipidemia in HIV-infected individuals treated with PIs. Together this may establish 
a pro-atherogenic profile and increase the risk for the onset of CVD.  
  Despite such progress the underlying molecular mechanisms responsible for HAART-induced 
cardio-metabolic side effects are poorly understood and little is known about the earliest events 
driving this process.  For the current study, we therefore hypothesized that HIV PI treatment 
enhances myocardial oxidative stress and concomitantly inhibits the UPS, thereby attenuating cardiac 
contractile function at baseline.  Since our previous ex vivo rat heart work (Chapter 3) 16 implicated 
altered calcium homeostasis in PI-mediated cardiac dysfunction, we further investigated calcium 
signaling and mitochondrial energetic regulators in our established rat model of chronic PI drug 
delivery. 
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Materials & Methods 
 
Animal model 
An additional but separate set of male Wistar rats, treated in an identical fashion to those in 
Chapter 3 were used. At the end of the 8-week treatment period rats were killed and a variety of 
analyses described below carried out on tissue collected immediately after sacrifice. All animals were 
treated in accordance with the Guide for the Care and Use of Laboratory Animals of the National 
Academy of Sciences (NIH publication No. 85-23, revised 1996) and performed with the approval of 
the Animal Ethics Committee of Stellenbosch University (South Africa).  
Drug administration 
 Drug administration occurred as described in Chapter 2.  
Histology 
 After 8 weeks, harvested tissues (heart, liver, adipose, pancreas and skeletal muscle) were 
fixed, processed and embedded in paraffin wax whereafter sections (4-5 μm) were stained with a) 
hematoxylin and eosin (HE) for general morphologic evaluation and b) Sirius red for detection of 
collagen deposits (fibrosis).   
Tissue lipid profile 
Isolated heart and liver tissues were also assessed for: total cholesterol, HDL, LDL/VLDL 
cholesterol and TG content according to the manufacturer’s instructions. Briefly, tissue cholesterol 
content was assessed in heart and liver homogenates (BioVision, Milpitas CA). HDL-cholesterol and 
LDL/VLDL-cholesterol were separated via differential centrifugation and precipitation buffer supplied 
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with the kit and a non-separated sample denoted for total cholesterol determination. Thereafter, a 
cholesterol master mix including cholesterol esterase was added to each sample in a 96-well 
microtiter plate in reaction buffer in addition to the standards supplied. The enzyme was not included 
in the reaction mixture for total cholesterol measurement. Incubation of samples with the reaction 
mixture for 1 hr at 37°C generated a color reaction and absorbance was measured in a colorimetric 
plate reader at 570 nm (Cecil CE2021 spectrophotometer, Cecil Instruments, Cambridge, UK). 
Cholesterol concentrations were determined from a standard curve and expressed as mmol/L.  
TGs in heart and liver tissue were also assessed by using a commercial kit (Abcam, Cambridge 
MA). Briefly, heart and liver tissue were homogenized in 5% NP-40 solution, heated to boiling point 
(100°C) to solubilize the TGs and subsequently centrifuged to remove insoluble material. Lipase was 
then added to convert TGs to glycerol and FA. Glycerol was then oxidized by the addition of a TG 
reaction mixture and the product generated reacted with a probe to generate color which was 
measured at 570 nm with a colorimetric plate reader (Cecil CE2021 spectrophotometer, Cecil 
Instruments, Cambridge, UK). Concentrations were extrapolated from the standard curve and 
expressed as mmol/L.  
Genetic profile 
 Real-time quantitative polymerase chain reaction (qPCR) analysis for gene expression was 
assessed in heart, liver and adipose tissue collected after 8 weeks of PI therapy. These experiments 
were performed in collaboration with Professor Monte Willis (McAllister Heart Institute, Department 
of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill NC). Total RNA was 
isolated from homogenized tissues (n=8) using the RNeasy® Mini Kit (Qiagen, Germantown MD) 
according to the manufacturer’s protocols as previously described 28,29.  First strand copy 
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deoxyribonucleic acid (cDNA) was made using the iScript™ cDNA synthesis kit (BioRad, Hercules CA) 
using 200 and 250 ng of RNA from liver, heart and adipose tissue, respectively, and included the 
Solaris synthetic RNA Spike Control (Thermo Scientific, Waltham MA) to test for reverse transcription 
and PCR inhibition. Samples that did not show significant inhibition (ΔCq < 3 compared to synthetic 
target alone, 69 of 72 samples) were diluted 20-fold in water and used for gene expression analysis. A 
total of three samples exhibited inhibition and were not used for qPCR analysis.  
We evaluated expression of the following genes: Acetyl-CoA carboxylase isoforms (accα: 
marker of FA synthesis; accϐ: marker of FA oxidation); Fatty acid synthase (fas: marker of FA 
synthesis); Glycerol-3-phosphate acyltransferase (mitochondrial) (gpam: marker of glycero-lipid 
synthesis); Hydroxyl-3-methyl-glutaryl-CoA reductase (hmgcr: marker of cholesterol synthesis); LDL 
receptor (ldlr: marker of LDL metabolism); SREBP isoforms (srebpf1/2: evaluate role of SREBPs); and 
glutamine fructose-6-phosphate amidotransferase (gfat1: Hexosamine biosynthetic pathway [HBP] 
marker). For all qPCR reactions, 2 μL of diluted cDNA (range  2 – 5 ng of cDNA) was used in technical 
triplicate reactions using LightCycler® 480 Probes Master mix (Roche, Indianapolis IN) for 5´ 
exonuclease chemistry with primers and probes per manufacturer specifications (Primers 
[forward/reverse]: actb – cccgcgagtacaaccttct/cgtcatccatggcgaact; hprt1 – 
gaccggttctgtcatgtcg/acctggttcatcatcactaatcac; pgk1 – ccagataacgaataaccaaagga/gacttggctccattgtcca; 
gapdh – agctggtcatcaatgggaaa/ atttgatgttagcgggatcg; g6pdh – 
ttatcatcatgggtgcatcg/aaggtgtcttcgggtagaagg; gusb – ctctggtggccttacctgat/cagactcaggtgttgtcatcg; tbp – 
cccaccagcagttcagtagc/ cccaccagcagttcagtagc; RNA - tgcaagccaattcccgaag/ ccattgtagtgaacagtaggac and 
Probes: 18S - Hs99999907_s1; acaca – Rn00573474_m1; acacb - Rn00588290_m1; fasn - 
Rn00569117_m1; gfpt1 - Rn01765492_m1; gpam - Rn00568620_m1, hmgcr - Rn00565598_m1, ldlr - 
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Rn00598442_m1, srebf1 - Rn01495769_m1; srebf2 - Rn01502638_m1) (Life Technologies, Grand 
Island NY; Roche, Indianapolis IN; Thermo Scientific, Waltham MA).  
Reactions were run on the LightCycler ® 480 qPCR instrument (Roche, Indianapolis IN). 
Relative quantification was calculated using the ΔCq method corrected for amplicon efficiencies 
(range = 1.9 – 2.1).  Reference gene fitness was determined by measuring a panel of genes: 18s, Actb, 
G6pdh, Gapdh, Hprt1, Pgk1, and Tbp. The most stable genes across the three conditions for each 
tissue was determined using the NormFinder algorithm 30,31; subsequently, the GeNorm algorithm 30,31 
was used to calculate the number of reference genes needed to maximize stability. For liver tissue, 
three reference genes were utilized (G6pdh, Hprt, Pgk1- variation (V) = 0.3; and 18s, Tbp, Gapdh - V = 
0.1, respectively). For heart tissue, four reference genes were used (18s, G6pdh, Hprt1, Tbp - V = 0.4). 
Relative target gene expression levels were determined using the ΔCq method followed by reference 
gene normalization as described 31.  
Western blotting 
Total protein was extracted from heart and liver tissue samples as described previously 32, 
while nuclear protein extraction was performed using the high-salt extraction method 33.   Protein 
concentrations for total and nuclear lysates were determined by the Lowry method. Target proteins 
included: cytosolic and nuclear SREBP-1, AMP-activated protein kinase (AMPK) and phosphorylated 
AMPK, peroxisome proliferator-activator gamma, coactivator 1 alpha (PGC-1α), 
sarcoplasmic/endoplasmic calcium ATPase (SERCA-2a), phospholamban (PLB) and phosphorylated 
PLB, calmodulin, calcineurin, calmodulin kinase II (CaMKII), nuclear factor of activated T-cells 3 
(NFAT3), nuclear respiratory factor 1 (NRF1), mitochondrial transcription factor A (mtTFA), and 
connexin 43 (Cx43).   
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Briefly, 20 μg protein was loaded onto a pre-cast gel (BioRad Laboratories, Hercules CA) and 
run at 250 mV until adequate separation of proteins occurred with the aid of a pre-stained marker. 
Protein was then transferred using a semi-dry turbo transfer system (BioRad Laboratories, Hercules 
CA) at 25 mV, 2.5 amps for 7 min and polyvinylidene fluoride (PVDF) membrane. The membrane was 
subsequently blocked with 1% milk in Tris-buffered saline with Tween 20 (TBS-T), washed in TBS-T and 
incubated in primary antibody overnight for the following proteins:  
 SREBP-1 (anti-rabbit SREBP-1 at 1:1,000, Santa Cruz Biotechnologies CA)  
 AMPKα (anti-rabbit AMPKα at 1:1,000; Cell Signaling, Danvers MA), phosphorylated 
AMPKα (anti-rabbit pAMPKα at 1:1,000; Cell Signaling, Danvers MA)  
 PGC-1α (anti-rabbit PGC-1α at 1:1,000, Cell Signaling, Danvers MA)  
 SERCA-2a (anti-sheep SERCA-2a at 1:1,000, Abcam, Cambridge MA)  
 PLB (anti-rabbit PLB at 1:1,000, Santa Cruz Biotechnologies, CA ), phosphorylated PLB 
(anti-rabbit pPLB at 1:1,000, Santa Cruz Biotechnologies, CA)  
 Calmodulin (anti-rabbit calmodulin at 1:1,000, Cell Signaling, Danvers MA)  
 Calcineurin (anti-rabbit calcineurin at 1:1,000, Cell Signaling, Danvers MA)  
 Phosphorylated CaMKII (anti-rabbit pCaMKII at 1:1,000, Cell Signaling, Danvers MA)  
 NFAT3 (anti-mouse NFAT-c4 at 1:1,000, Santa Cruz Biotechnologies, CA)  
 NRF1 (anti-rabbit NRF-1 at 1:1,000, Santa Cruz Biotechnologies, CA)  
 mtTFA (anti-mouse mtTFA at 1:1,000, Santa Cruz Biotechnologies, CA)  
 Cx43 (anti-mouse Connexin 43 at 1:1,000, Santa Cruz Biotechnologies, CA) 
Appropriate secondary antibody (anti-rabbit/mouse/sheep) was used between 1:2,000 and 1:4,000 
dilution for all blots. Visualization and detection of protein expression were performed with enhanced 
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chemiluminescence (ECL). Briefly, the horseradish peroxidase (HRP) linked to the secondary antibody 
catalyzes the conversion of luminol to 3-aminophthalae which is detected via emission of light at 428 
nm. This signal is then detected via a digital camera after exposing the membrane to luminol and 
converted into a digital image on a computer. Protein detection was performed using standard 
methods 32 where expression was determined by the adjusted percentage volume (intensity units  of 
pixels of band x mm2) after background subtraction and normalized to β–actin (anti-rabbit β-actin at 
1:1,000; Cell Signaling, Danvers MA) or Ponceau stain (Ponceau S Red stain, Sigma Aldrich, St. Louis 
MO) to correct for variations in loading (Quantity One Software v.4.6.9, BioRad Laboratories, Hercules 
CA). Thereafter, the average adjusted percentage volume of the sham group was calculated by the 
software  and subsequently represented as 100% separately (sham values were represented as a 
percentage of the average). Values obtained for vehicle and PI were also expressed as a percentage of 
the average of the sham. This was done for each gel (separately) before all values were combined in 
the statistical program and presented as percentage of the control. Histone H3 was initially utilized for 
nuclear protein loading control, but yielded too much variation (though not significant, p>0.05) to be 
used effectively and indicated that this protein might be post-translationally modified via the PI 
treatment as it is monitored via the UPS 34. Since Ponceau stain yielded similar results for cytosolic 
and nuclear (in terms of low variability), all subsequent membranes for the different cellular fractions 
were stained with Ponceau Red (Fig. 1). Initial data accumulation utilized β–actin normalization, 
whereas later on Ponceau Red stain was used. Both normalizations are indicated for the specific gels 
in the Results section. 
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Figure 1. Different methods of normalizing nuclear extracts in heart tissue (n=6). Both Histone H3 
antibody and Ponceau Red stain were used to provide a normalizing control for nuclear extracts. 
Histone H3 blots reveal more variation between groups than with the Ponceau stain, though neither 
attains significance. Data presented as mean ± SEM. PI – protease inhibitor. 
 
Proteasome activity 
Cardiac chymotrypsin-like, trypsin-like, and caspase-like activities of the proteasome were 
assayed in collaboration with Professor Emmanuel Bourdon (University of La Reunion, France) using 
fluorogenic peptides (Sigma-Aldrich, St Louis MO): Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin 
(LLVY-MCA at 25 µM), N-t-Boc-Leu-Ser-Thr-Arg-7-amido-4-methylcoumarin (LSTR-MCA at 40 µM) and 
N-Cbz-Leu-Leu-Glu-b-naphthylamide (LLE-NA at 150 µM), respectively, as described before by us 35.   
Specific activity of ATPase 
ATP synthase specific activity (Abcam, Cambridge MA) in heart tissue was determined 
according to the manufacturer’s instructions.  Briefly, ATP synthase was immunocaptured via 
monoclonal antibody precoated ELISA plates and activity measured as decreased NADH absorbance 
(oxidation to NAD+) at 340 nm.  The quantity was measured via coupling of a Complex V antibody 
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conjugated to alkaline phosphatase and measured as increased color development at 405 nm. ATP 
content was determined as the amount of luciferase produced in proportion to the amount of ATP at 
560 nm (FLx800 Fluorometer, Bio-tek Instruments Inc, Winooski VT) and expressed as relative 
fluorescent units (RFU).   
ATP content 
 ATP content in heart samples were measured using a commercial kit (Enlighten® ATP Assay 
System Bioluminescence Detection Kit, Promega, Madison WI). Briefly, the quantity of ATP was 
measured via the following reaction:  
ATP + D-Luciferin + O2  Oxyluciferin + AMP + PPi + CO2 + Light 
This light-emitting reaction is measured at 560 nm spectrophotometrically (Cecil CE2021 
spectrophotometer, Cecil Instruments, Cambridge, UK) with light emitted proportional to the ATP 
concentration within the sample. ATP concentration was expressed as percentage change versus the 
sham.  
Calcium content 
 The calcium content of the myocardium was determined colorimetrically (Calcium Detection 
kit, Abcam, Cambridge MA). Briefly, heart lysate up to 50 μL was added to a 96-well microplate and 
the chromogenic agent 0-cresolphthalein added to the wells with gentle mixing. A chromogenic 
complex is then formed with the calcium ions present within the samples. Assay buffer was the added 
and samples allowed to incubate briefly and subsequently analyzed spectrophotometrically at 575 nm 
(Cecil CE2021 spectrophotometer, Cecil Instruments, Cambridge, UK). Concentrations were 
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extrapolated from a standard curve and normalized to the volume of lysate added and expressed as 
mg/dL. The physiologically acceptable range of calcium is 0.4-100 mg/dL (0.1-25 mM). 
Superoxide concentration 
Superoxide levels were evaluated by homogenizing cardiac tissue in 10 volumes of 10% 
perchloric acid and centrifuged at 3000 x g for 20 min (Spectrofuge 24D microcentrifuge, Labnet 
International Inc., Edison NJ). Subsequently 100 µL of protein-free supernatant was incubated with 50 
µL of 0.25 mM lucigenin in a white-walled 96-well plate for 5 min at room temperature.  
Chemiluminescence was detected at 430 nm / 452 nm and expressed as RFU x106 per mg tissue with 
a fluorometer (FLx800 Fluorometer, Bio-tek Instruments Inc, Winooski VT).  
SOD determination 
SOD (Enzo Life Sciences, Farmingdale NY) activity was measured in total myocardial protein 
lysates and mitochondrial preparations (prepared according to Boudina et al 36) as detailed in the 
manufacturer’s instructions. Briefly, xanthine and oxygen are converted to uric acid and H2O2 by the 
addition of xanthine oxidase XO. The superoxide anion produced converts WST-1 to WST-1 formazan, 
which may be detected colorimetrically at 450 nm (Cecil CE2021 spectrophotometer, Cecil 
Instruments, Cambridge, UK). The addition of SOD will reduce the superoxide anion concentration and 
decrease the rate of WST-1 formazan formation, thereby indicating the activity of SOD. SOD activity is 
calculated as the amount of present in the extract that incurs 50% inhibition of the reaction as 
units/μL. 
Glutathione determination 
Total, free and oxidized glutathione levels were determined colorimetrically at 405 nm (Cecil 
CE2021 spectrophotometer, Cecil Instruments, Cambridge, UK) with a probe that reacts with the free 
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thiol group on glutathione (GSH) (Arbor Assays, Ann Arbor MI).   Samples were treated with 2-
vinylpyridine blocked free glutathione to allow for the measurement of oxidized and total glutathione. 
Concentration was extrapolated from a standard curve and expressed as percentage of control 
(sham). 
Carbonylation content 
Protein carbonyls are formed by a variety of oxidative mechanisms and are sensitive indices of 
oxidative injury. Protein carbonylation in heart tissue was determined by the carbonyl ELISA assay 
developed in the GEICO laboratory (Université de La Réunion, Saint Denis de La Réunion, France) 
based on recognition of protein-bound dinitrophenolhydrazine (DNPH) in carbonylated proteins with 
an anti-DNP antibody 37. 
Here 5 µL of protein from heart tissue lysates (0.2-0.6 µg) was denatured by adding 10 µL 12% 
sodium dodecyl sulphate (SDS) solution. Subsequently, proteins were derivatized to DNP hydrazone 
with 10 µL of DNPH solution (10 mM in 6 M guanidine hydrochloride, 0.5 M potassium phosphate 
buffer, pH 2.5). DNPH is a chemical compound that specifically reacts and binds to carbonylated 
proteins. Samples were incubated at room temperature for 30 min and the reaction was neutralized 
and diluted in coating buffer (10 mM sodium carbonate buffer, pH 9.6) to yield a final protein 
concentration of 0.2 - 0.6 ng/µL.  
Diluted samples were added to wells of a Nunc Immuno Plate Maxisorp (Dutscher, Brumath, 
France) and incubated at 37°C for 3 hrs, and thereafter washed 5x with phosphate-buffered saline 
with Twee-20 (PBS-T, 0.1%) between each of the following steps: blocking the wells with 1% BSA in 
PBS-T overnight at 4°C; incubation with anti-DNP antibody (Sigma-Aldrich, St Louis MO)  (1:2,000 
dilution in PBS-T [0.1%]/BSA [1%]) at 37°C for 3 hrs; incubation with HRP-conjugated polyclonal anti-
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rabbit immunoglobulin (GE Healthcare, Mannheim, Germany) (1:4,000 dilution in PBS-T [0.1%]/BSA 
[1%]) for 1 hr at 37°C; addition of 100 µL of 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate solution 
and incubation for 10 min before stopping the coloration with 100 µL of 2 M sulphuric acid. 
Absorbances were read at 490 nm against the blank (DNP reagent in coating buffer without protein) 
with a Fluostar microplate reader (BMG Labtech, Ortenberg, Germany). Results are expressed as 
percentage of absorbance compared to sham values after normalization with protein concentrations. 
Catalase activity 
The catalase activity assay is based on the properties of catalase enzyme to reduce H2O2 into 
O2 and water H2O 
38. Assays were carried on about 80 μg of heart protein lysate in 25 mM Tris–HCl 
(pH 7.5).  Blanks were measured at 240 nm just before adding 80 µL of H2O2 (10 mM final) to start the 
reaction. Catalase activity was determined by measuring the absorbance decrease of H2O2 at 240 nm 
(Cecil CE2021 spectrophotometer, Cecil Instruments, Cambridge, UK). The decomposition of H2O2 is a 
first order reaction type following H2O2 concentration and the rate constant K for the overall reaction 
is given by: 
                                                )log(*
3.2
t
zero
DO
DO
t
K

  
Each measurement was considered with 4 replicates and data are expressed as catalytic unit (U) per 
mg of total protein. 
Statistical analyses 
 One-way ANOVA was performed for all experimental groups with a Bonferroni post-hoc test to 
compare differences between groups. Significance is indicated on graphs when p<0.05 and results are 
expressed as mean ± SEM. Where applicable, if significance was only obtained versus sham in relation 
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to PI treatment, but not to vehicle; data were then re-analyzed and the vehicle chosen to represent 
100%. This ensured that all statistical data reported here are correct.  
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Results 
 
Ex vivo heart function revealed that PI treatment detrimentally affects cardiac contractility at baseline 
(Chapter 3). Therefore, the aim of this study was to investigate metabolic, contractile and calcium-
related markers to investigate underlying molecular mechanisms.  
Histological analyses of a variety of tissues, including cardiac tissues, indicated no evidence of 
abnormal growth or ultrastructure (Fig. 2) between the treatment groups. Fibrosis was not found in 
any of the tissues when assessed via Sirius red staining (data not shown).   
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Figure 2. Histological analyses of 8 weeks PI therapy in multiple organs (n=3). Sections are 4-5μm 
(x100 magnification) and each image is representative of the group. PI – protease inhibitor. 
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Next, cholesterol content in two highly metabolically active tissues, i.e. heart and liver, was 
assessed. No significant alterations to total cholesterol and LDL/VLDL cholesterol content was found 
in cardiac tissues (p>0.05 vs. matched controls) (Fig. 3, top panel). Interestingly, myocardial HDL-
cholesterol was significantly elevated with 8 weeks of chronic PI therapy (0.316 ± 0.025 vs. sham 
0.240 mmol/L ± 0.008, p<0.01; vs. vehicle 0.242 mmol/L ± 0.004, p<0.01). Hepatic tissue displayed a 
notable increase in the TG content (0.618 ± 0.036 vs. sham 0.478 mmol/L ± 0.024, p<0.05; vs. vehicle 
0.431 mmol/L ± 0.026, p<0.01) (Fig. 3, lower panel). 
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Figure 3. Heart and liver lipid profile in response to 8 weeks PI treatment (n=8). Data are presented 
as mean ± SEM. *p<0.05, **p<0.01 vs. sham; #p<0.05, ##p<0.01 vs. vehicle. HDL – high-density 
lipoprotein, LDL/VLDL – low-density/very low-density lipoprotein, PI – protease inhibitor. 
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To determine mechanisms responsible for early metabolic changes, we evaluated lipid and 
cholesterogenic genes in heart and liver tissues.  Here PI treatment enhanced cardiac gpam 
expression (p<0.001 vs. sham), although this was not significant vs. vehicle-treated rats.  However, 
hepatic accϐ and hmgcr gene mRNA expression were upregulated in the PI group (p<0.05) (Fig. 4). 
 
Figure 4. Gene profile at baseline (n=8). Metabolic genes assessed via RT-PCR in response to 8 weeks 
PI treatment. Data presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 vs. sham; #p<0.05, 
##p<0.01 vs. vehicle. acc – acetyl coA carboxylase, fas – fatty acid synthase, gfat – glutamine fructose-
6-phosphate amidotransferase, gpam - glycerol-3-phosphate acyltransferase (mitochondrial), hmgcr – 
hydroxyl-3-methyl-glutaryl-coA reductase, ldlr – low-density lipoprotein receptor, PI – protease 
inhibitor, srebf – sterol regulatory element binding factor. 
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Since our gene data point towards a molecular effect of PIs, we assessed protein levels of the 
sterol sensor, SREBP-1. Here the data showed no significant alterations within neither cytosolic nor 
nuclear compartments in terms of peptide expression (p>0.05 vs. sham and vehicle) (Fig. 5). Due to 
time differences in analysis of blots, cSREBP-1 was normalized to β-actin, while nSREBP-1 (completed 
at a later stage) was normalized to Ponceau S Red stain. 
 
 
Figure 5. Expression of SREBP-1 at baseline in response to 8 weeks PI treatment (n=6-8). The 
activated form of SREBP-1 occurs at 68kDa. Data presented as mean ± SEM, and blot images are 
representative of the group. cSREBP was normalized to β-actin and nSREBP-1 to Ponceau S Red stain 
(refer to text for explanation). cSREBP-1 – cytosolic, nSREBP-1 – nuclear, PI – protease inhibitor, SREBP 
– sterol regulatory element binding protein. 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
179 
 
Since energy homeostasis plays a critical role in heart function, we also evaluated myocardial 
ATP levels, AMPK expression and ATPase activity. Myocardial ATP content remained unchanged in 
response to 8 weeks PI therapy as did the expression of AMPK and phosphorylated AMPK (p>0.05 vs. 
matched controls) (Fig. 6). 
 
Figure 6. ATP content and AMPKα expression in response to 8 weeks PI therapy (n=6-8). A) Cardiac 
ATP content; B) AMPKα; and C) Phosphorylated AMPKα expression. Representative blots are shown in 
the top right corner. Data presented as mean ± SEM, and blot images are representative of the group 
and all blots are normalized to β-actin. AMPK – AMP-activated protein kinase, ATP – 5’-adenosine 
triphosphate , PI – protease inhibitor. 
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ATPase activity, expressed as the ratio of activity versus quantity, was not significantly altered 
in PI-treated hearts (Fig. 7). 
 
Figure 7. Cardiac ATPase specific activity at baseline (n=8). A) ATPase specific activity (a ratio of the 
activity versus quantity); B) ATPase activity; and C) ATPase quantity. Data presented as mean ± SEM. 
Vehicle is considered 100% (see Methods and text for explanation). ATPase – 5’-adenosine 
triphosphate synthase, PI – protease inhibitor. 
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We next evaluated the effects of PI treatment on the cardiac UPS system and our data 
demonstrate lowered chymotrypsin-like and caspase-like, but not trypsin-like proteasomal activities 
(p<0.05) (Fig. 8). In parallel, global ubiquitination of cytosolic proteins increased more than 2-fold with 
PI administration (p<0.05 vs. sham and vehicle) (Fig. 9).  
 
 
Fig 8. Proteasomal activity following 8 weeks PI treatment (n=8). LLVY (chymotrypsin-like activity), 
LSTR (trypsin-like activity), and LLE (caspase-like activity) of the proteasome. Data presented as mean 
± SEM. **p<0.01, ***p<0.001 vs. sham; #p<0.05 vs. vehicle. PI – protease inhibitor. 
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Fig 9. Global ubiquitination of cytosolic and nuclear proteins in response to PI therapy (n=5-8). 
Ubiquitination determined per lane (between 17 and 170 kDa) and expressed as global ubiquitination. 
Data presented as mean ± SEM, and blot images are representative of the group. All blots are 
normalized to Ponceau S stain. *p<0.05 vs. sham; #p<0.05 vs. vehicle. nUbiquitin – nuclear 
ubiquitination, PI – protease inhibitor. 
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To gain additional insight regarding PI-mediated contractile dysfunction, markers regulating 
ion channel homeostasis, electrical conductance and protein degradation were investigated.  Here 
myocardial expression of the gap junction protein Cx43 (marker for electrical conductance), SERCA-2a 
(cardiac calcium transporter) and pPLB (SERCA-2a regulator) increased with PI treatment (p<0.05) 
(Fig. 10).   
 
Fig 10. Protein expression of contractile regulators following PI treatment (n=6-8). A) Connexin 43; 
B) SERCA-2a; and C) Phosphorylated PLB. *p<0.05 vs. sham; #p<0.05, ##p<0.01 vs. vehicle. Data 
presented as mean ± SEM, and blot images are representative of the group. Blots normalized to 
Ponceau S stain. pPLB – phosphorylated phospholamban, PI – protease inhibitor, SERCA – 
sarcoplasmic/endoplasmic reticulum calcium ATPase. 
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We next assessed calcium and mitochondrial energetic signaling markers and found that 
myocardial calcium content was below the homeostatic range of 0.4 mg/dL with chronic PI therapy 
(0.165 ± 0.026 vs. sham 0.599 mg/dL ± 0.150, p>0.05; vs. vehicle 0.456 mg/dL ± 0.190, p>0.05) (Fig. 
11A). PIs also significantly downregulated the expression of the calcium-binding protein calmodulin 
(Fig. 11B), while calcineurin within the cytosolic - but not nuclear - compartment was upregulated 
(Fig. 11C, D). However, pCaMKII levels remained unchanged while dephosphorylated nuclear NFAT3 
expression (140 kilodaltons [kDa]) increased versus controls (p<0.05 vs. sham and vehicle) (Fig. 11E, 
F). The hyperphosphorylated form of NFAT3 (160 kDa) was undetectable in nuclear samples.  
Stellenbosch University  http://scholar.sun.ac.za
185 
 
 
Fig 11.  Calcium pathway protein expression in response to PI therapy (n=6-8).  A) Calcium content; 
B) Calmodulin; C) Cytosolic calcineurin; D) Nuclear calcineurin; E) pCaMKII; and F) Dephosphorylated 
nuclear NFAT3. Data presented as mean ± SEM, and blot images are representative of the group. Blots 
are normalized to Ponceau S stain (not shown). *p<0.05, **p<0.01 vs. sham; #p<0.05, ##p<0.01 vs. 
vehicle. NFAT3 – nuclear factor of activated T-cells 3, pCaMKII – phosphorylated CaMKII, PI – protease 
inhibitor. 
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The expression of PGC-1α was significantly upregulated in PI-treated heart tissue (Fig. 12A) 
while no changes were found for mitochondrial biogenesis markers (mtTFA, NRF-1) (Fig. 12B, C). 
 
 
Figure 12. PGC-1α pathway protein expression in response to 8 weeks PI treatment (n=6-8). A) PGC-
1α; B) mtTFA; and C) NRF-1. Data presented as mean ± SEM, and blot images are representative of the 
group. Blots are normalized to Ponceau S stain (not shown). ***p<0.001 vs. sham, ###p<0.001 vs. 
vehicle. mtTFA – mitochondrial transcription factor A, NRF – nuclear respiratory factor, PGC-1α – 
peroxisome proliferator-activator receptor gamma, coactivator 1 alpha, PI – protease inhibitor.  
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Markers of the redox system were next evaluated as we hypothesized that PI therapy can 
detrimentally alter the redox status within the heart. Myocardial SOD activity measured in both 
cytosolic and mitochondrial fractions were robustly increased with PI treatment versus matched 
controls (p<0.001) (Fig. 13A, B). Superoxide production, however, did not follow the same 
relationship and was not significantly altered with PI therapy (p>0.05 vs. sham and vehicle) (Fig. 13C). 
Myocardial superoxide production was unaltered after 8 weeks of PI therapy.   
 
Figure 13. Baseline myocardial SOD activity and superoxide production in response to 8 weeks PI 
treatment (n=8). A) Cytosolic; and B) Mitochondrial SOD activity; C) Superoxide content. Data 
presented as mean ± SEM. ***p<0.001 vs. sham, ###p<0.001 vs. vehicle. PI – protease inhibitor, SOD – 
superoxide dismutase. 
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Further investigation into redox pathways such as glutathione revealed a similar relationship 
in that no alterations were apparent after 8 weeks of PI therapy. Here, oxidized glutathione (GSSG), 
total reduced and free glutathione (GSH) as well as the ratio (GSH/GSSG) were not significantly 
different in PI-treated hearts versus matched controls (p>0.05) (Fig. 14). The carbonylation content of 
myocardial proteins as well as catalase activity did not differ for any of the experimental groups 
(p>0.05) (Fig. 15). 
 
Figure 14. Glutathione levels in response to PI treatment (n=8). A) Oxidized glutathione (GSSG); B) 
Reduced total glutathione (GSH); C) Free glutathione (GSH); and D) GSH/GSSG ratio. Data presented 
as mean ± SEM. PI – Protease inhibitor. 
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Figure 15. Carbonylation content and catalase activity in response to 8 weeks PI therapy (n=8). A) 
Myocardial protein carbonylation content; and B) Catalase activity. Data presented as mean ± SEM. PI 
– protease inhibitor. 
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Discussion 
 
Although HAART markedly improves the quality of life and prognosis of HIV-infected individuals, it 
also elicits cardio-metabolic side–effects in the long-term. Since molecular mechanisms underlying 
this process are poorly understood, we evaluated the early cardio-metabolic changes in a novel rat 
model of PI treatment. The main findings of this study are: 1) PI-treated rats exhibit lipid 
abnormalities; and 2) Rats exposed to PIs display altered myocardial ubiquitin proteasome and 
calcium-handling pathways.  
 PI-treated rats exhibit lipid abnormalities. 
Previous studies demonstrated that a significant proportion of HAART patients develop impaired 
glucose tolerance, IR and T2DM 10,39.  Here our data revealed that PI-treated rats displayed weight 
gain together with elevated serum LDL-cholesterol (Chapter 2) and cardiac/hepatic tissue TG levels, 
identifying perturbed lipid metabolism as a relatively early occurrence.  Although not focusing on 
initial PI-mediated changes, previous work also reported that lipid derangements are one of the 
commonest side-effects triggered by Lopinavir/Ritonavir usage 40.   Moreover, clinical studies indicate 
that altered fat partitioning (i.e. lipodystrophy) is common with PI treatment 7,41,42 compared to overt 
increases in weight gain, and that this occurs within the first year of therapy. Our data show that the 
onset of IR likely follows at a later stage in the progression of cardio-metabolic dysfunction following 
PI treatment.   In support, the HOMA-IR assessment that is usually strongly linked to IR and T2DM, 
was not activated in our model (Chapter 2).   
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How exactly does PI treatment induce the changes in lipid metabolism here observed? PI 
treatment induced gene expression of accϐ and hmgcr in the liver that would be expected to enhance 
FAO and cholesterol synthesis, respectively.  There were also early signs of elevated cardiac gpam 
expression (although not statistically significant versus all matched controls), while it was robustly 
upregulated in adipose tissue.  The gene expression results therefore indicate that the higher serum 
LDL-cholesterol levels may result from greater adipose TG synthesis and subsequent export to the 
liver and heart.  Here increased hepatic hmgcr expression may enhance VLDL production and with a 
corresponding elevation in the availability of circulating LDL-cholesterol.  Interestingly, the serum 
total cholesterol remained unchanged, indicating that it is unlikely at this early time point that 
circulating LDL-cholesterol is affected and that the changes reside at the genetic level within our 
model. 
Since PIs may also have direct transcriptional effects that trigger gene expression, we also 
assessed whether SREBPs – well-known transcriptional regulators of several lipid and cholesterol 
synthesis genes 22 - are implicated in the observed gene induction.   We found no significant 
differences when analyzing SREBP expression (gene and protein levels) in liver and heart tissues, and 
suggest that other transcriptional modulators that regulate lipid and cholesterol genes may be 
involved 26.  An alternate explanation may relate to the fact that that Ritonavir is a reversible and 
competitive inhibitor of specific 20S proteasome subunits 24.  Since the UPS also plays a key role to 
regulate SREBP-1 binding to target gene promoters (mediating its degradation) 26,27, lower UPS 
activity may lead to more SREBP-1 remaining bound to gene promoter(s). This in turn could result in 
greater induction of target genes, even though total SREBP expression levels were unaltered.   These 
possibilities are currently being pursued in our laboratory. 
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Together our study shows that early changes induced by PI treatment resembles the MetS, a 
combination of risk factors that predispose to the future onset of IR, T2DM and CVD.   Moreover, the 
higher serum LDL-cholesterol levels mirror a pre-atherogenic state that may eventually trigger the 
onset of various cardiac complications, e.g. acute MI.   
Rats exposed to PIs display altered myocardial ubiquitin proteasome and calcium-handling 
pathways with decreased contractile function. 
What are the underlying mechanisms whereby PI administration impairs contractile function?   
Our results show no significant remodeling of hearts exposed to PIs, i.e. lack of ultrastructural 
changes, fibrosis and cardiac hypertrophic response. We also evaluated markers for myocardial 
oxidative stress since others found a link between PI exposure and elevated ROS production 17–19, but 
found no evidence of damaging effects of myocardial oxidative stress at baseline (no changes in 
degree of protein carbonylation). However, PI-treated hearts exhibited augmented myocardial SOD 
activity suggesting that increased oxidative stress is blunted by intracellular defense systems.  Thus 
these data indicate that harmful effects of previously reported PI-induced ROS likely occur at a later 
stage during the HAART regimen.  In agreement, our colleague (Ms Tarryn-Lee Fischer, MSc student at 
the Department of Physiological Sciences, Stellenbosch University) established that there was no ROS-
mediated induction of several non-oxidative glucose metabolic pathways in PI-treated rats 43.    
Importantly, we did not differentiate between the three SOD species/isoforms that are found within 
the cytosol and mitochondria. Total SOD content was measured and it is assumed that the cytosolic 
compartment contains a greater amount of the copper/zinc SOD (Cu/Zn SOD) isoform, while the 
mitochondrial compartment is richer in manganese SOD (MnSOD). Thus we interpret our data 
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cautiously as to the relative contributions of the SOD isoforms to total SOD content and subsequent 
detoxification capacities. 
The heart functional data (Chapter 3) revealed attenuated contractile function without 
significant alterations to heart rate. Here the ±dP/dt findings implicate the myocardial calcium 
handling pathway, as diastolic calcium is a key determinant of contractile function and calcium 
signaling 44.  Since PI treatment decreased and increased myocardial UPS activity and ubiquitination, 
respectively, this may lead to an accumulation of contractile protein aggregates and impaired cardiac 
contractility and signaling pathways.  For example, protein turnover of Cx43, PLB and SERCA-2a are all 
regulated by the UPS 45–49 and may explain the higher expression levels found here and before by us 
16.  This in turn may result in detrimental effects on contractile function, e.g. others established that 
altered Cx43 expression can precede arrhythmias, ventricular fibrillation and incorrect signal 
propagation in the long-term 50–55.   
This data reveal that PI treatment lowers myocardial calcium levels and elevates SERCA-2a 
protein expression, and further attenuates and increases calmodulin and pPLB expression levels, 
respectively.  In parallel, we found increased myocardial calcineurin and NFAT3 expression levels.  
Together these findings indicate that perturbed calcium handling may contribute to the PI-mediated 
contractile dysfunction found in our experimental model.  Of note, others found that cardiac-specific 
calcineurin overexpression resulted in enhanced pPLB and SERCA-2a expression and diminished 
phosphorylation and redistribution of Cx43 56.  This was associated with depressed contractility and 
cardiac hypertrophy. Here the authors proposed that Cx43 may be a downstream target of calcineurin 
and that attenuated Cx43 levels may be linked to perturbed gap junction assembly and 
arrythmogenesis 56.   We propose that a similar scenario exists in our model and that greater 
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calcineurin activation may be linked to elevated Cx43 expression that could compromise gap junction 
function and ultimately decrease cardiac output.  Increased SERCA-2a and pPLB expression may occur 
as a result of lower myocardial UPS and have also been implicated as downstream transcriptional 
targets of calcineurin 56.  Thus elevated SERCA-2a and pPLB expression may represent an adaptive 
response by PI-treated hearts to improve calcium handling and cardiac function under these 
conditions (refer model proposed in Fig. 16). Higher calcineurin activation also leads to increased 
dephosphorylation and translocation of NFAT3 to the nucleus for activation of downstream targets, 
e.g. PGC-1α and pro-hypertrophic genes 57,58. However, since the calcineurin-NFAT3 pathway did not 
result in cardiac hypertrophy in our model, we are of the opinion that longer-term activation may 
eventually result in a hypertrophic response.  
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Figure 16. Model demonstrating the influence of PI therapy on calcium handling and cardiovascular 
dysfunction. The data show that 8 weeks of PI treatment increases calcineurin expression and inhibits 
proteasomal activity. Downstream targets include Cx43, PLB and SERCA-2a. Alterations to these 
pathways can lead to disrupted calcium signaling and impaired electrical signal propagation. 
Ultimately, calcium homeostasis and heart function are impaired in the long term. Cx43 – connexin 
43, P - phosphate, PLB - phospholamban, PI – protease inhibitor, SERCA – sarcoplasmic/endoplasmic 
reticulum calcium ATPase.  
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Since myocardial PGC-1α was upregulated this implies that PIs exert initial effects at the 
mitochondrial level.  PGC-1α is a well-described transcriptional regulator of mitochondrial biogenesis 
59,60 (refer to Fig. 7, Chapter 1) and we propose that higher expression levels may represent an early 
compensatory response to energetic stress.  In agreement with this notion, NRF-1 and mtTFA 
expression remained unaltered while we previously found no changes for myocardial ATP levels and 
AMPKα  expression following 8 weeks of PI administration 16.  It is likely that reduced UPS activity in 
PI-treated hearts may contribute to the increased PGC-1α levels here observed.  In support, others 
established that lower UPS-mediated protein turnover in fibroblasts resulted in PGC-1α stabilization 
and mitochondrial biogenesis 61, while it can also be rapidly degraded in the nucleus 62.    
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Conclusions 
 
In conclusion, our study demonstrates that early changes triggered by PI treatment include increased 
body weight and serum LDL-cholesterol levels, together with decreased cardiac function.  
Furthermore, PI exposure inhibits the myocardial UPS and leads to elevated calcineurin and Cx43 
expression that may contribute to cardiac contractile dysfunction.  Thus our study alerts to cardio-
metabolic side-effects of PI treatment and we propose that further clinical studies are needed to 
evaluate these pathways in HIV+ patients on chronic HAART.   
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